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                                          INTRODUCTION 
 
Siddha system of medicine is the ancient, unique, potent, and holistic medical 
system among all the systems of medicine in the world. It is a traditional system of 
healing that originated in south India, which flourished between 2500BC and 
1700AD
(1)
. Generally, origin of this system is associated with Siddhars, the ascetics 
who aimed for ageless body to achieve their highest spiritual goal. Prevention and 
cure are the basic aims of all systems of medicine whereas the Siddha system has in 
addition the transcendental motivation of what might be called the immortality of the 
body. 
 
  Siddha system firmly believes that whatever changes which occurs in the 
world around us (Macrocosm- Andam) is certain to create an impact on the health of a 
man (Microcosm). So if any alteration in nature of macrocosm (Universe World) 
spontaneously affect the human body function. This concept of Siddha medicine 
could be rightly considered as the pioneer efforts of environmental protection for a 
healthy living. 
 
Siddha concepts are mainly based on panchabootha theory. According to 
panchabootha hypothesis the Universe originally consisted of atoms which 
contributed to five basic elements. They are Earth, Water, Fire, Air and Space, which 
were corresponded to the five senses of human body and they were the fundamentals 
of all the corporal things in the World
(2)
. This five elements combine to form the 
Tridoshas or humours whose balance is essential for the maintenance of health. 
 
Apart from this, Siddha system of medicine consists of three humours namely 
Vatham, Pitham and Kabham which normally exist in the ratio of 1:1/2:1/4. 
Derangement of the ratio in these humours lead to vatha, pitha and kabha diseases
(3)
. 
 
The anatomical, physiological and psychological functions of the body are 
known to be intricately and inherently connects as all of them emerge from the five 
elements. The structural components or the tissue components of the body are 
composed of seven types of materials called Udalthathus or Udalkattukal. If one 
thathu is defective, each connected thathu is affected, thereby triggering a chain 
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reaction of impairment at times throughout the entire tissue system. The formation of 
the thathus is through the food substances. The use of healthy foods is essential for 
sustaining the thathus.  
 
The classical Siddha literature Aathmaratchamirtham Ennum Vaithiya 
Sangiragam quoted about Soothaga vaayu. The clinical features of Soothaga vaayu 
may be correlated with PCOS in modern aspects. Siddha literature pararasasekaram 
cite that any imbalance in three humours may inhibit the release of ovum from the 
ovaries. This may be related to the PCOS due to hormonal imbalance. 
                  
                            
                                -                                 
 
PCOS is a heterogenous, multisystem endocrinopathy in women of 
reproductive age with various metabolic disturbances and a wide spectrum of clinical 
features such as menstrual abnormalities, obesity, and hyperandrogenism. This 
disease was discovered by and named as Stein-Leventhal syndrome in 1935. It has 
been attributed to several causes including change in lifestyle, diet and stress. 
 
Current incidence of PCOS (5-6%) is fast increasing lately due to change in 
the lifestyle and stress. It is also becoming a common problem amongst adolescent, 
developing soon after puberty. Amongst infertile women, about 20% is attributed to 
anovulation caused by PCOS. The World Health Organization estimates that PCOS 
affects 116million women worldwide (3-4% of the people in the world)
(4)
. PCOS 
produces symptoms approximately in 5-10% of women during the reproductive age 
(12-45 years)
(5)
.  
      
Although several medications and treatment methods are available in modern 
medical field prevalence of PCOS is still uncontrollable in reproductive women due to 
lifestyle changes, diet and stress. Proper medication with lifestyle changes can 
decrease the occurrence of PCOS in women.  
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Having completely convinced with the literary evidences available in Siddha 
medicine, I have chosen Soothaga vaayu as my dissertation work which correlates 
with Poly cystic ovarian syndrome (PCOS) as described in the modern medical 
system. 
 
KALINGATHI ENNAI is a herbal formulation mentioned in Siddha text 
Sikitcharatna Deepam Irandam Pagamagiya Vaithiya Chinthamani is indicated as an 
effective medicine for SOOTHAGA VAAYU (PCOS). Siddha system of treatment 
consist 32types of internal medicine and 32types of external medicine. Ennai 
(Medicated oil) is one among the 32 types of internal medicine. Medicated oils are 
classified into twelve types based on origin and five varieties by the mode of 
applications. As Kalingathi ennai is given internally it comes under Kudi ney. The 
active principles of the medicine get dissolved in the oil and it is absorbed depending 
upon administration. 
 
On the whole as a compound medicine KALINGATHI ENNAI may be an 
effective, easy available with more potency and lesser side effects in the treatment of 
SOOTHAGA VAAYU.  
 
In recent days, reproductive age group women’s expects relief without any 
adverse effects for this disease. So I believed that the Siddha medicine Kalingathi 
ennai gives the best solution in Soothaga vaayu. Treatment is arrived for restoring 
balance to the mind and body system. Diet, lifestyle, asanas and meditation are 
advised to the patients, which play a major role not only in maintaining health but also 
in curing disease
(6)
. 
 
So I preferred to select Soothaga vaayu (Poly cystic ovarian syndrome) as the 
dissertation topic with the Siddha preparation Kalingathi ennai. 
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AIM AND OBJECTIVES 
AIM: 
       The purpose of this study is to evaluate the safety and efficacy of Siddha herbal 
formulation “KALINGATHI ENNAI” in the treatment of SOOTHAGA VAAYU. 
OBJECTIVES: 
 Collections of various Siddha literature of the study. 
 Herbal Identification and authentication of the trial medicine. 
 To prepare the trial medicine “KALINGATHI ENNAI” as per Standard 
Operative Procedures medicine preparation. 
 To study the evaluation of Siddha trial medicine “KALINGATHI ENNAI” for 
SOOTHAGA VAAYU. 
 To evaluate the biochemical, physicochemical analysis of the trial medicine. 
 To evaluate the safety profile like acute toxicity, sub acute toxicity of the trial 
medicine in animal models as per OECD guidelines 423&407. 
 To evaluate the pharmacological analysis of OVULATION INDUCING 
ACTIVITY for my trial medicine. 
 To correlate the Siddha aspects of SOOTHAGA VAAYU to POLY CYSTIC 
OVARIAN SYNDROME of Modern medicine with aspect of aetiology, 
classification, pathology, prognosis and clinical features. 
 To gather the Siddha diagnostic parameters by Mukkutram, Udalthathukkal, 
Uyirthathukkal, and Envagai thervugal. 
 To use modern parameters to confirm the diagnosis and prognosis of the 
disease. 
 To make a clinical observation about the disease in relation of age, sex, 
occupation, socio economic status and diet.  
 The haematological analysis, urine analysis, radiological studies and follicular 
studies will be done to all patients. 
 All patients are subjected to thorough investigation before and after treatment. 
 To find out the statistical analysis and efficacy of the trial medicine through 
clinical study. 
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               REVIEW OF LITERATURE SIDDHA ASPECT 
      SOOTHAGA VAAYU 
 
VERUPEYARGAL (SYNONYMS): 
 Soothaga soolai 
 Dhoora soolai 
 Karpa vaayu 
 
IYAL (DEFINITION):    
A menstrual disease marked by pain at the epigastrium, corpulency, 
enlargement of the abdomen. It is due to the uterus being choked up with 
accumulation of the menses arising from heat combining with the deranged vayu in 
the system
(7)
. 
 
SOOTHAGAM UNDAGUM VITHAM: 
“                         
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                      ”(8) 
                                                                                                      SIDDHA ASPECT 
 
 Page 7 
 
 
The physiology of women’s menstrual cycle is illustrated in the Siddha 
literature magnificiently as before modern technologies had been developed. The 
uterus of women is attached to the ovaries with fimbria on either side through the 
fallopian tube. 
   
The menstrual cycle for healthy women takes place with an interval of 30days. 
Endometrial shedding takes place for three days. The amount of blood lost per day in 
a cycle is calculated for a normal women is about 30.6 ml. (6 kazhanju- 6*5.1 = 30.6 
ml) 
 
NOI VARUM VAZHI (ETIOLOGY): 
According to the text, Arivaiyar Chinthamani,  
          “                           
                                       
                                            
                                            ”(9) 
 
 Venereal diseases. 
 Infections. 
 Increased body heat due to excessive physical activity. 
 Coitus at the time of menstrual cycle. 
 
According to the text, Dhanvanthiri Vaithiyam (1
st
 part),  
“                            
                                
                               
                             ”(10) 
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 Diseases and food poisoning. 
 Retention of lochia. 
 Increased vayu produces uterine disorders. 
 
According to the text, Agathiyar Kanma Kaandam 300, 
“                             
                          
                     
                         
                     
                         
                      
                    ”(11) 
 
SOOTHAGA VAAYU NOI KURIKUNANGAL (CLINICAL FEATURES):  
                    
                                     
                     
                  
                     
                       
                                  
                               (12) 
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 Amenorrhoea due to accumulation of vaayu and agni in ovaries. 
 Anovulation. 
 Lower abdominal pain. 
 Headache and Low back pain. 
 Central obesity. 
 
SOOTHAGA VAAYU IN VARIOUS SIDDHA TEXTS 
 
(i) According to the text, Arivaiyar Chinthamani,  
                         
               
                          
                      
                          
                  
                            
                 
                      
              
                           
               
                       
                      (13) 
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 Scanty menstruation. 
 Lower abdominal pain. 
 Pain in the breast. 
 Pain in the upper and lower limbs. 
 Loss of appetite. 
 Excessive sleep. 
 Head ache. 
 Anaemia. 
 Excessive sleep. 
 
(ii) According to the text, Arivaiyar Chinthamani, 
                      
                         
                        
                    
                         
                          
                     
                     (14) 
 
 Amenorrhoea. 
 Lower abdominal pain. 
 Head ache. 
 Obesity. 
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(iii) According to the text, Pathinensiddharkal Aruliseidha Naadi Sasthiram 
“                           
                          
                         
                              ”(15) 
 
If the three Naadis are diminished and found mingled with one another then 
 it indicates vaayu accumulated in uterus. 
 
(iv) According to the text, Agasthiyar Vaithiya Kaaviyam 1500 
                           
                        
                      
                             (16) 
 
 Loss of appetite. 
 Diarrhoea. 
 
These are due to accumulation of vaayu in ovaries.  
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(v) According to the text, Thirumoolar Karukadai Vaithiyam -600 
“                               
                      
                                    
                                   ”(17) 
 
(vi) According to the text, Brammamuni Vaithiya Soothiram -390 
 “                       
                        
                               
                         
                 
                         
                         
                          ”(18) 
 
 Amenorrhoea. 
 Body pain. 
 Gastritis. 
 Pricking pain in foot and nail buds. 
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OTHER TERMS OF KARPA NOIGAL SIMILAR TO SOOTHAGA VAAYU 
 
In Thirumular Karukkadai Vaithiyam 600 described as 
“                         
                           
                      
                         ”(19) 
 
In Pathinen Siddhargal Paadiya Vaithiya Sillarai Kovai described as 
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                                   (20) 
      
Types of Uterine disorders: 
1. Abnormalities in the uterine cavity 
2. Endometrial Polyp in the uterus 
3. Fibroid uterus 
4. Any infection in the uterus 
5. Amenorrhoea 
6. Bulky uterus 
 
1. KARPA SOOLAI: 
                                      
                                   
                                      
                                   (21) 
-Aaviyalikum Amudhamurai Churrukam 
  
 Pseudopregnancy. 
 Abdominal pain. 
 Fatigue. 
 
These are the symptoms of  karupai soolai due to accumulation of vaayu and 
agni in ovaries. 
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2. KARPA VAAYU: 
                                     
                                     
                                        
                                       (22) 
                        -Dhanwanthri Vaidhiyam Part-1 
 
The symptoms mentioned in the above text due to derangement of vaayu 
include inhibition of regular menstrual flow, dysmenorrhoea, miscarriage, low 
back pain, and constipation. 
 
3. KARPA SURONITHAM: 
                                    
                             
                                     
                                   (23) 
                   -Dhanwanthri Vaidhiyam Part-2 
 
In Karpa  suronitham due to the effect of vaayu in lower abdomen mentioned 
in the above text it has the symptoms of dysmenorrhoea, oligomenorrhoea, increased 
salivation, giddiness, irregular menstruation and miscarriage. 
4. KARPA VIPURUDHI: 
“                      
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                     .”(24) 
                                           -Aathmaratchamirthamenum vaithiya sara sangiragam 
  
 Amenorrhoea 
 Headache 
 Dysmenorrhoea 
 Constipation 
 Infertility 
 Body pain 
 
5. KARPA VAAYUVIN GUNAM: 
“                          
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                ”.(25) 
                                                     -Sarabenthirar vaithiya muraigal 
 
 Dysmenorrhea 
 Lower abdominal pain 
 Pain in the breast 
 White discharge 
 
6. SOOTHAGA KIRANI: 
“                         
                           
                              
                   ”. 
 Dysmenorrhea 
 Irregular menstruation 
 
MUKKUTRA IYAL (The Tridosha theory) 
Tridosha is otherwise called as mu as they remain as doshas and form as the 
causative factor for the appearance of disease. This is only a part of the 
Panchabootha thathuvam and forms the humoral pathology in Siddha system of 
medicine similar to hormones in modern physiology. 
 
 A right understanding of tridosha theory in all its varied aspects is necessary 
for a rational diagnosis and effective treatment. 
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“                                  
                                            
                                         
                                               ”(26) 
                -Noi Nadal Noi Mudhal Nadal Thirattu (Part-1) 
 
               : 
   “                        
                                         
                             
                                     
                                     
                                     
                                 
                            .”(27) 
                                                               -Siddha Maruthuvanga Surrukam 
    
The three humours vatha, pitha, kabha are living all over the body. The vatha 
is distributed below the umblicus, pitha is distributed between the umblical and 
epigastric region and kabha is distributed above the epigastric region. 
 
Panchaboothams are manifested in the body as three vital forces, 
 Vatham (Air + Space) 
 Pitham (Fire) 
 Kapham (Water + Earth)(28) 
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S.NO 
 
TRIDOSHAS 
 
           SEATS 
 
  PROPERTIES 
 
  FUNCTIONS 
              
1                    VATHAM 
 
Below the navel, 
urinary bladder, 
intestine, pelvis, 
umblical cord, thigh, 
bone, skin, nerve 
endings, joints, 
musculature, hair 
root.   
 
Dryness, 
lightness, 
clearness, 
coolness, mobile 
formless. 
 
Stimulation, 
respiration, 
thinking, 
sensory 
functions, 
coordination of 
the physical 
constituents, 
reflex actions. 
           
2  
 
 PITHAM 
 
Between the heart and 
navel, sweat, lymph, 
blood, stomach, 
urinary bladder, heart, 
saliva, eye and skin.     
 
Dry, cold, light, 
subtle, keen, 
soft, liquid, 
bitter.   
 
Body 
temperature, 
digestion of 
food, vision, 
sweat. 
         
3 
 
 KABHAM 
 
Above the heart, 
stomach, fat, sperm, 
uvula, bone marrow, 
blood, nose, nerves 
eyes, joints. 
 
Heavy, cold, 
sweet, stable and 
slimy.  
 
It gives strength 
of joints, shiny 
appearance of 
skin, moistens 
food, cools the 
eye, softness, 
firmness. 
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FUNCTIONS OF VALI: 
“                          
                     –        
                          
                  ”.(29) 
-Siddha Maruthuvanga Surrukam 
 
  Vatha is said to be first originated from the natural element air and then with 
the combination of the other two elements, heat and water developed as vatha, and 
involution of typical type of synthetic chemical changes occur before it is 
represented in the human body as a humour of vatha dosha. This is classified into 
ten varieties. 
        
S.NO 
    TYPES 
OF VATHAM 
             
         FUNCTIONS 
IN 
SOOTHAGAVAAYU 
 
 
   1            Piraanan 
It is mainly responsible for 
respiration and it is 
necessary for proper 
digestion and utilisation of 
food materials. 
Normal 
 
 
      2 
Abaanan 
This is responsible for all 
downward movements such 
as passing urine, stools, 
semen, menstrual flow etc. 
Irregular menstruation, 
Constipation. 
 
 
 
3 
Viyanan 
This is responsible for sense 
of touch extension and 
flexion of the part of the 
body and distribution of the 
nutrients to various parts of 
the body. 
Low back pain, Lower 
abdominal pain. 
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    4  Uthaanan 
Responsible for all upward 
visceral movements such as 
nausea, vomiting etc. 
Normal 
 
    5 Samaanan 
This aids in proper 
digestionand it controls the 
other types of vaayu. 
Affected 
  
6 Naagan 
Helps in opening and 
closing of the eyelids. 
Normal 
 
7 Koorman 
Responsible for vision, 
lacrimation and yawning. 
Normal 
 
 
    8 
Kirugaran 
Induces appetite, salivation, 
all secretions in the body 
including nasal secretions 
and sneezing. 
Normal 
 
 
9 
Thevathathan 
Induces and stimulates a 
person to become alert, get 
anger, to quarrel, to sleep. 
Normal 
 
 
 
10 
Dhananjeyan 
Resides in the cranium and 
produces bloating of the 
body after death. This 
leaves from the body after 
3days of death, forming a 
way through the skull. 
_ 
 
In Soothagavaayu patients Abaanan, Viyanan, Samanan are mainly affected.  
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PITHAM: 
  “                            
                      –    
                             
                  ”.(30) 
      -Siddha Maruthuvanga Surrukam 
  Pitha is said to be originated first from the natural element of heat and then 
with the combination of other two elements viz. air and water, developed as pitha 
and after the involution of synthetic chemical changes it is represented in the human 
body as a humour of pitha dosha. This is also sub-divided into five types. 
 
S.NO 
TYPES 
OF PITHAM 
 
FUNCTIONS 
IN SOOTHAGAVAAYU 
1 Analagam 
It promotes appetite and 
helps in digestion. 
Normal 
2 Ranjagam 
It is responsible for the colour 
and contents of the blood. 
Normal 
3 Praasagam 
It gives complexion to the 
skin. 
Normal 
4 Saathagam 
It controls the whole body 
and is held responsible for 
fulfilling a purpose. 
Lack of regular 
menstruation. 
5 Aalosagam 
It is responsible for the 
perception of vision. 
Normal 
In Soothagavaayu patients Sathagam is mainly affected. 
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KABHAM: 
 “                             
                       –       
                               
                      ”.(31) 
                        -Siddha Maruthuvanga Surrukam 
 Kabham is said to be originated first from the natural element namely water and then 
with the combination of other two elements air and heat, it develops as kapha and after the 
involution of synthetic chemical changes it is represented in the human body as humour in 
kabha dosha. This kabha dosha is said to possess the destruction power. This is of its coldness 
which when markedly increased overlaps other two doshas vatha and pitha which are 
responsible for the respiration, circulation of blood and maintain of head and remains as the 
signs of life with the result death occur.       
 
S.NO 
TYPES 
OF KABHAM 
 
FUNCTIONS 
IN 
SOOTHAGAVAAYU 
1 Avalambagam 
Lies in respiratory organ, controls 
the heart and circulatory system 
and other types of Kabham. 
Normal 
2 Kilethagam 
Found in stomach, makes the 
food moist soft and helps to be 
digested. 
Normal 
3 Pothagam 
Responsible for the sensory 
Perception of taste. 
Normal 
4 Tharpagam 
Present in the head and 
responsible for coolness of both 
eyes, sometimes may be referred 
to as cerebrospinal fluid. 
Normal 
5 Santhigam 
Necessary for the lubrication and 
the free movements of the joints. 
Low back pain 
In Soothagavaayu patients Santhigam is affected. 
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UDAL THATHUKKAL (SEVEN PHYSICAL CONSTITUENTS): 
                The human body is made of seven basic physical constituents. These 
constituents should be in harmony and function normally. Any variation in them will 
lead to their functional deviations. The Natural characters of the seven physical 
constituents are mentioned. 
S.NO 
SAPTHA 
THATHUKKAL 
FUNCTIONS 
IN 
SOOTHAGA 
VAAYU 
1 Saaram 
Responsible for the growth and 
development. It keeps the individual in 
good temperament and it enriches the 
blood. 
Tiredness 
2 Seneer 
Responsible for the colour of blood and 
for the intellect, nourishment, strength, 
vigour and valour of the body. 
Normal 
3 Oon 
Gives look able contour to the body as 
needed for the physical activity. It feed 
the fat next day and gives a sort of 
plumpness to the body. 
Obesity 
4 Kozhupu 
Lubricates the organs to facilitate 
frictionless functions. 
Normal 
5 Enbu 
Supports and protects the vital organs, 
gives the definite structure of the body 
and responsible for the posture and 
movements of the body. 
Low back 
pain 
6 Moolai 
Nourishes the bone marrow and brain 
which is the centre that controls other 
systems of body. 
Normal 
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7 Suronitham It is responsible for the reproduction. 
Irregular 
menstruation 
 In Soothagavaayu patients Saram, Oon, Enbu, Suronitham are mainly affected. 
 
PINIYARI MURAIMAI (DIAGNOSIS): 
          It means the method of diagnosing the disease, 
  “                 
                     
                   
                   
                 
                
                  
                   ”.(32) 
     -Sikitcharathna Deepam Ennum Vaidhiya Nool 
 
 The above poem describes that diagnosis is very important for the physician to 
treat the disease. 
     “                                
                               
                              
                  ”.(33) 
       -Theraiyar Yamaga Venba 
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Four steps are followed in diagnosing the disease. They are, 
1. Poriyaalaridhal 
2. Pulanaltherdhal 
3. Vinaathal 
4. Envagaithervu 
 
1.PORIYAALARIDHAL: 
  The physician should carefully observe the changes that occur ithe five sensory 
organs (Porigal) of the patient. 
 
2.PULANALTHERDHAL: 
   The physician carefully applies his five senses of perception, smell, taste, 
vision, touch and sound to understand the condition of the patient. 
 
3.VINAATHAL: 
           The physician should interrogate about the patients name, age, occupation, 
socio economic status, food habits, history of past illness, history of present illness, 
family history, marital status, menstrual history and frequency of pain. 
 
ENVAGAI THERVUKAL: 
“                       
                      ”(34) 
                    -Noi Nadal Noi Mudhal Nadal Thirattu 
   Nowadays advanced diagnostic tools have been developed by modern bio-
medical scientists. But Siddhars have given eight diagnostic methodological tools. 
They are called as Envagaithervu. 
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EIGHT FOLD SYSTEM OF CLINICAL ASSESSMENTS: 
Siddhars have given eight diagnostic methodological tools. They are, 
1. Naadi 
2. Sparisam 
3. Naa 
4. Niram 
5. Mozhi 
6. Vizhi 
7. Malam 
8. Moothiram 
NAADI: 
  “                                     
                                
                                  
                                     ”.(35) 
     -Sikitcha Rathna Deepam Ennum Vaidhiya Nool 
  
 The heart is the special organ of the body. It supplies blood all over the body. 
Naadi is a Unique pulse reading method to denote any dysfunction of the body. 
 
NAADI MOONDRAIYUM NAADIDUM KAALAI: 
  “                   
                                        
                                  
                                      
                              
                               ”.(36) 
                           -Noi Nadal Noi Mudhal Nadal Thirattu 
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 From these stanzas it is very clearly understood that the diagnosis based on Naadi 
will bring out the best results. Pulse diagnosis is the confirmative diagnosis. Normally 
the pulse is recorded in a radial artery in the right hand for the male and left hand for 
the female by keeping the ring finger, the middle finger, and the index finger on it 
after gently scrubbing the area. It is one unit in vatha as felt by the ring finger, and a 
half unit in pitha as felt by the middle finger and one fourth unit in kapha as felt by 
the index finger. The different diseases could easily be diagnosed with the aid of the 
pulse. 
          “                               
                                     
                                  
                                ”.(37) 
      -Noi Nadal Noi Mudhal Nadal Thirattu 
VADHA NAADI: 
  “                     
                                 
                             
                                         
                        
                              
                         
                           ”.(38) 
                -Noi Nadal Noi Mudhal Nadal Thirattu 
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“                           
                                 
                                     
                                  
                                  
                                 ”.(39) 
      -Pathinensiddhargal Aruliseidha Naadi Sasthiram  
 
“                             
                              
                          
                                  ”.(40) 
       - Pathinensiddhargal Aruliseidha Naadi Sasthiram 
 
VADHA ROGANGAL: 
“                      
                                
                               
                               
                          
                                
                    ”.(41) 
                    -Sikitcha Rathna Deepam Ennum Vaidhiya Nool 
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S.NO 
ENVAGAI   
THERVU 
 
CHARACTER 
IN 
SOOTHAGA VAAYU 
1 Naadi --- Vatha naadi 
2 Naa 
Coated 
                    Taste 
Colour 
Tongue is coated and pale. 
3 Niram Skin colour 
Hyperpigmentation in 
cubital fossa, armpits, neck, 
thigh, etc [A.Nigricans] 
4 Mozhi Articulation and speech No abnormality in speech. 
5 Vizhi Niram (pallor, icterus) Pale in anaemic condition. 
6 Sparism 
      Touch 
       Pain 
Temperature 
 
No abnormality 
 
 
7 Malam 
Niram – Colour 
Irugal, Illagal 
Consistency 
Manam – Odour 
Constipation 
8 Mootthiram 
Niram – Colour 
Manam – Smell 
Nurai – Forth 
 Eadai – Specific gravity 
Enjal – Deposit 
No abnormality 
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NEERKURI: 
 “                      
                                   
                           
                                 
                                 
                               ”.(42) 
      -Noi Nadal Noi Mudhal Nadal Thirattu 
        
   The early morning urine of the patient is analysed by dropping a drop of 
gingelly oil on the surface of the urine sample. By dispersing under the sunlight 
without any external disturbances of the urine sample the accumulation, formations 
and changes can be noted. 
 
NEIKURI: 
  “                         
                                       
                                   
                                     
                              
                         ”.(43) 
      -Noi Nadal Noi Mudhal Nadal Thirattu 
  
 The urine is kept on the kidney tray in sunlight, on a non-windy condition. Then 
it should be examined by dropping a drop of gingelly oil gently, with a stick. If the oil 
spreads like a snake it indicates Vatha, a ring indicates Pitha, and if it floats like a 
pearl it indicates Kapha. 
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   “                  
                           
                             ”.(44) 
                      -Siddha Maruthuvanga Surrukam 
 
 In Soothagavaayu when a drop of oil is put in the patient’s freshly collected urine 
the oil drop spread like a snake which indicates vatha neer. 
        
      The eight tools of diagnosis are used not only for that purpose, but also to study 
the prognosis. The urine examination is widely used to study the prognosis. If the oil 
drop for the urine examination spreads in the shape of rice pot, a dwarf, betel leaf, 
horse, the prognosis is good. But if it spreads like a bird, dog, lion, pig, monkey, 
scorpion, cat, human being, the prognosis is bad. If the drop spreads rapidly the 
prognosis is bad. If the drop spreads slowly the prognosis is good and the disease is 
easily curable.  
 
LINE OF TREATMENT: 
Administration of the trial medicine: 
   Kalingathi Ennai-15ml with warm water, once a day before food. 
 
Duration of treatment: 
   5days, three consecutive menstrual cycles. 
 
Yogasanam: 
   All patients were advised to do yogasanam. Yoga is a part of Siddha 
medicine which plays a major role in not only treating the disease but also in 
preventing the disease. Women should keep in mind that they should not do asanas 
during their monthly menstrual cycle. After, the period ends, asanas can be practised 
and it will give a lot of benefits
(45)
.(Fig 1.1-1.5). 
 
 
 
                                                                                                      SIDDHA ASPECT 
 
 Page 33 
 
 Piranayamam 
 Dhanurasanam 
 Bujangasanam 
 Badhakonasanam 
 Patchimothasanam 
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            Fig 1.1 Pranayamam                                      Fig 1.2 Bujangasanam 
 
 
                 
             Fig 1.3 Dhanurasanam                                      Fig 1.4 Badhakonasanam 
   
                                              
                                                     Fig 1.5 Patchimothasanam 
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         MODERN ASPECT 
 
FEMALE REPRODUCTIVE SYSTEM: 
The female reproductive system consists of external and internal genitalia 
organs respectively. 
 
EXTERNAL GENITALIA: 
The external female genitalia are referred to as vulva. It consists of the 
following structures namely, 
                    1 .MONS PUBIS 
                    2. LABIA MAJORA 
                    3. LABIA MINORA 
                    4. CLITORIS  
                    5. OPENING OF THE URETHRA (MEATUS) 
                    6. HYMEN 
                    7. PERINEUM 
          
The vestibule is the space into which the vagina and urethra open. The urethra 
opens just anterior to the vagina. 
         
The vestibule is bordered by a pair of thin, longitudinal skin folds called the 
labia minora. 
          
Lateral to the labia minora two prominent rounded folds of skin called the 
labia majora are present. The two labia majora unite anteriorly into an elevation of 
tissue over the pubic symphysis called the mons pubis. The lateral surface of the labia 
majora and the surface of the mons pubis are covered with coarse hair. 
         
The medial surface of the labia majora are covered with numerous sebaceous 
and sweat glands. The space between the labia majora is called the pudendal cleft. 
        
A small erectile structure is called the clitoris is located in the anterior margin 
of the vestibule. The two labia minora unite over the clitoris to form a fold of skin 
called the prepuce. 
                                                                                                   MODERN ASPECT 
 
 Page 36 
 
      The hymen is a thin fold of mucous membrane that separates the lumen of the 
vagina from the urethral sinus. 
        
      The perineum is the short stretch of skin starting at the bottom of the vulva and 
extending to the anus. 
 
INTERNAL GENITALIA: 
      The internal reproductive organs are situated in the pelvis between the bladder and 
rectum. They are held in space within the pelvis by a group of ligaments.  
          
The internal genitalia includes 
1. VAGINA 
2. CERVIX 
3. UTERUS 
4. FALLOPIAN TUBES 
5. OVARIES 
 
VAGINA: 
 The vagina is a muscular, hollow tube that extends from the vaginal 
opening to the cervix of the uterus. It is also known as the birth 
canal. 
 It is a fibro muscular tube of about 10cm long. 
 It is a female organ of copulation and allows menstrual flow and 
child birth. In young females it is covered by a thin mucous 
membrane called hymen. 
 
CERVIX: 
 The cervix is the lower, narrow portion of the uterus where it joins 
with the top end of the vagina. 
 During menstruation, the cervix stretches open slightly to allow the 
endometrium to be shed. 
 During childbirth, contractions of the uterus will dilate the cervix up 
to 10cm in diameter to allow the child to pass through. 
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UTERUS: 
 The uterus is a hollow, pear-shaped organ which is divided into 
parts namely cervix, which is the lower part that opens into the 
vagina, and the main body of the uterus, called the corpus. 
 The uterine wall is composed of three layers, 
 Outer serous layer or perimetrium, 
 Middle muscular layer or myometrium, 
 Inner most layer endometrium. 
 The endometrium consist of simple columnar epithelial cells with 
underlying connective tissue layer. The superficial part of 
endometrium is sloughed down during menstruation.  
 
FALLOPIAN TUBES: 
 There are two uterine tubes also called uterine tubes or oviducts. 
 One uterine tube is associated with each ovary. 
 The uterine tubes extend from the ovaries to the uterus.  
 They open pear the ovary to receive the oocyte and the opening is 
surrounded by long thin processes called fimbriae. 
 As soon as oocyte is ovulated, it comes into contact with the 
surface of the fimbriae and the cilia on the fimbrial surface sweep 
the oocyte into the uterine tube. 
 Fertilization usually occurs in the uterine tube near the ovary. 
 
OVARIES: 
 The two ovaries are small oval shaped organs attached to the 
ligaments that suspend them in the pelvic cavity and from the 
ligament of the uterus. 
 The suspensory ligament extends from each ovary to the lateral 
body wall and the ovarian ligament attaches the ovary to the uterus. 
 A layer of visceral peritoneum called tunica albuginea covers the 
ovary. The outer cortex of the ovary is made up of dense 
connective tissue containing ovarian follicles. Each of the ovarian 
follicles contains an oocyte the female germ cell.
(46),(47)
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  PHYSIOLOGY OF MENSTRUAL CYCLE 
 
DEFINITION: 
 The term menstrual cycle refers to the series of changes that 
occur in sexually mature non pregnant females and that 
culminate in menses. 
 The term menses is derived from Latin word which means 
month. Menses is a period of mild haemorrhage during which 
part of the endometrium is sloughed and expelled off from the 
uterus. 
 The commencement of menstrual cycle is called menarche and 
usually starts at the age of 12-15 years. 
 Permanent cessation of menstrual cycle in old age is called 
menopause and it usually occurs at the age of 45-50 years. 
 
DURATION OF MENSTRUAL CYCLE: 
The menstrual cycle is about 28 days long and the changes are controlled by 
the secretions of FSH and LH from the anterior pituitary. 
 
SYMPTOMS OF MENSTRUAL CYCLE:  
 Acne 
 Feeling tired 
 Trouble sleeping 
 Swollen or tender breasts 
 Upset stomach, bloating, constipation or diarrhoea 
 Headache or backache 
 Appetite changes or food cravings 
 Joint or muscle pain 
 Trouble with concentration or memory 
 Tension, irritability, mood swings or crying spells 
 Anxiety or depression. 
Symptoms vary from woman to woman. 
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PHASES OF MENSTRUAL CYCLE 
The day count for menstrual cycle begins on the first day of menstruation 
when blood starts to come out of the vagina. In this section, the length of menstrual 
cycle has been assumed to be 28 days (which is the average among women). The 
entire duration of a menstrual cycle can be divided into four main phases:   
 Menstrual phase (From day 1 to 5) 
 Follicular phase (From day 1 to 13) 
 Ovulation phase (Day 14) 
 Luteal phase (From day 15 to 28) 
 
MENSTRUAL PHASE (DAY 1-5): 
    Menstrual phase begins on the first day of menstruation and lasts till the 5
th
 
day of the menstrual cycle. The following events occur during this phase: 
 The uterus sheds its inner lining of soft tissue and blood vessels which exits 
the body from vagina in the form of menstrual fluid. 
 Blood loss of 10 ml to 80 ml is considered as normal. 
 Abdominal cramps may occur. These cramps are caused by the contraction of 
the uterine and the abdominal muscles to expel the menstrual fluid. 
 
FOLLICULAR PHASE (DAY 1-13): 
This phase also begins on the first day of menstruation, but it lasts till the 13
th
 
day of the menstrual cycle. The following events occur during this phase:   
 The pituitary gland secretes a hormone that stimulates the egg cells in the 
ovaries to grow. 
 One of these egg cells begins to mature in a sac like structure called follicle. It 
takes 13 days for the egg cell to reach maturity. 
 While the egg cell matures, its follicle secretes a hormone that stimulates the 
uterus to develop a lining of blood vessels and soft tissue called 
endometrium.
(48) 
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OVULATION PHASE (DAY 14): 
  On the 14
th
 day of the cycle, the pituitary gland secretes a hormone that causes 
the ovary to release the matured egg cell. The released egg cell is swept into the 
fallopian tube by the cilia of the fimbriae. Fimbriae are finger like projections 
located at the end of the fallopian tube close to the ovaries and cilia are slender hair 
like projections on each Fimbria. 
 
LUTEAL PHASE (DAY 15-28): 
      This phase begins on the 15 th day and lasts till the end of the cycle. The 
following events occur during this phase: 
 The egg cell released during the ovulation phase stays in the fallopian tube 
for 24 hours. 
 If a sperm cell does not impregnate the egg cell within that time, the egg 
cell disintegrates. 
 The hormone that causes the uterus to retain its endometrium gets used up 
by the end of the menstrual cycle. This causes the menstrual phase of the 
next cycle to begin
(49)
. 
 
MENSTRUAL CYCLE: 
The term menstrual cycle refers to the series of changes that occur in sexually 
mature non pregnant females and that culminate in menses. 
 
The term menses is derived from Latin word which means month. Menses is a 
period of mild haemorrhage during which part of the endometrium is sloughed and 
expelled off from the uterus. 
 
The menstrual cycle is about 28 days long and the changes are controlled by the 
secretions of FSH and LH from the anterior pituitary.  
 
The ovarian cycle and the endometrial cycle together constitute menstrual 
cycle. 
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OVARIAN CYCLE: 
The development and maturation of a follicle, ovulation and formation of 
corpus luteum and its degeneration constitute an ovarian cycle. All these events occur 
within 4 weeks. Ovarian cycle consists of Recruitment of groups of follicles, 
Selection of dominant follicle and its maturation, Ovulation, Corpus luteum 
formation, Demise of corpus luteum. 
 
RECRUITMENT OF GROUPS OF FOLLICLES (PREANTRAL PHASE): 
            About 20 antral follicles proceed to develop in each cycle. The growth and 
differentiation of primordial follicles are under the control ofFSH. Unless the follicles 
are rescued by FSH at this stage, they undergo atresia. Oocyte is enlarged to the size 
of a follicle. Oocyte is surrounded by acellular barrier of glycoprotein cells called 
Zonapellucida. 
 
Flattened outer single layered pregranulosa cells become 
multilayeredgranulosa cells. Nutrition to the oocyte is maintained through the gap 
junctions between granulosa cells and oocyte. 
In selection of a dominant follicle the development of antrum containing 
secondary or vesicular follicle from the solid primary follicle depends on FSH. 
Follicular fluid is produced within theca internae. The fluid filled spaces coalesce to 
form an antrum. At day 5-7, one of the follicle becomes dominant and undergoes 
further maturation. Follicle with highest antral concentration of oestrogen and lowest 
androgen: oestrogen ratio and whose granulosa cells contain the maximum receptors 
for FSH, becomes the dominant follicle. The rest of them become atretic by day eight. 
There is marked enlargement of the granulosa cells with lipid inclusion. The cells 
adjacent to the ovum are arranged radially and are called corona radiate. The fully 
mature Graffian follicle just prior to ovulation measures about 20mm and is composed 
of Theca externa, Theca interna, Membranagranulosa, Granulosa cell layer, Discus 
proligerus and Antrum containing vesicular fluid
(50)
. 
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OVULATION: 
           The dominant follicle, shortly before ovulation reaches the surface of the 
ovary. The oocyte completes the first meiotic division. The follicular wall near the 
ovarian surface becomes thinner. Stigma develops as conical projection and 
penetrates the outer surface layer of ovary. Stigma is soon closed by a plug of plasma. 
 
CAUSES: 
1. Endocrinal - LH surge - FSH rise 
2. Stretching factor 
3. Contraction of the micromuscles 
           Menstruation is unrelated to ovulation and anovular menstruation is 
quite common during adolescence, following childbirth and in women approaching 
menopause
(51)
. 
 
CORPUS LUTEUM: 
          After ovulation, the ruptured Graffian follicle develops into corpus luteum. The 
life cycle is divided into four stages. 
1. Proliferation 
2. Vascularisation 
3. Maturation 
4. Regression 
 
ENDOMETRIAL CYCLE: 
           The endometrium is the lining epithelium of the uterine cavity. It consists of 
surface epithelium, glands, stroma and blood vessels. Two distinct divisions are seen. 
They are 
1. Basal zone (stratum basalis) 
2. Superficial functional zone (stratum functionalis) 
 
BASAL ZONE: 
          This zone is about one third of the total depth of the endometrium and lies in 
contact with the myometrium. The zone is uninfluenced by hormone and no cyclic 
changes are observed. 
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          After shedding of the superficial part during menstruation, the regeneration 
occurs from this zone. It is about 1mm in thickness. 
 
FUNCTIONAL ZONE: 
          This zone is under the influence of ovarian hormones, oestrogen and 
progesterone. The changes during anovulatory cycle can be divided into 4 stages 
1. Stage of Regeneration 
2. Stage of Proliferation 
3. Stage of Secretion 
4. Stage of Menstruation 
 
(i) STAGE OF REGENERATION: 
             Regeneration of the endometrium starts before the menstruation ceases and 
is completed 2-3 days after menstruation. 
 
(ii) STAGE OF PROLIFERATION: 
It extends from 5th day to 14th day until ovulation. During this stage the level of 
ovarian oestrogen is raised. In these stage blood vessels, glands and other 
components undergo proliferation. 
 
(iii) STAGE OF SECRETION: 
              The changes of components are due to the combined effect of oestrogen 
and progesterone. The progesterone act on the endometrium. It starts on day 15 
and ceases 5-6 days prior to menstruation. Thickness of endometrium reaches its 
highest 5-6mm. 
 
(iv) STAGE OF MENSTRUATION: 
      Due to damage of blood vessels bleeding occurs. The blood along with the 
superficial functional layer is shed into the uterine cavity. A normal menstrual 
cycle depends on cyclical ovarian steroid secretions which in turn are controlled by 
the pituitary and the hypothalamus and to some extent by the thyroid and adrenal 
glands. So the hypothalamo-pituitary-ovarian axis is important
(52)
. 
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HORMONAL INTERACTIONS IN THE REPRODUCTIVE FUNCTIONS: 
               Neuroendocrinology with vast hormonal interactions is responsible for 
menstrual cycle and reproductive functions in women.  A normal menstrual cycle 
depends on cyclical ovarian steroid secretions which in turn are controlled by the 
pituitary and the hypothalamus and to same extend by the thyroid and adrenal 
glands. It is therefore essential to understand the hypothalamic-pituitary-ovarian 
axis in normal women. 
             The following hormones play the major role, 
1. Gonadotropin releasing hormone (GnRH)- hypothalamus 
2. Follicle stimulating hormone (FSH)- anterior pituitary 
3. Luteinising hormone (LH)- anterior pituitary 
4. Oestrogen- ovary 
5. Progesterone- ovary 
6. Inhibin- ovary 
7. Testosterone- ovary 
 
1.GONADOTROPIN RELEASING HORMONE (GnRH): 
 GnRH is secreted by the hypothalamus which modulates the neural 
control of FSH and LH by the anterior pituitary. 
 GnRH is released in a pulsatile manner and the pulsatility and 
amplitude of its release varies with various phases of the menstrual 
cycle. 
 In pre-ovulatory phase it pulses every 60mins but slows down in 
luteal phase to one in 3 hours. GnRH is continuous in males but 
pulsatile in females. 
 The hypothalamus is controlled by higher cortical centres especially 
temporal lobe. Emotional upsets stimulate or depress the H-P-O axis 
and disturb the menstrual cycle. 
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2. FOLLICLE STIMULATING HORMONE(FSH): 
 FSH controls the ripening of the primordial follicles and in 
combination with the luteinizing hormone activates the secretion of 
oestrogen. 
 Its activity starts as menstruation is ceasing, it reaches the peak by 7th 
day and then declines to disappear around 18
th
 day. Another small 
peak occurs in premenstrual phase. 
 Low FSH causes defective folliculogenesis and short or defective 
corpus luteal phase. 
 
3.LUTEINIZING HORMONE: 
 In combination with FSH it activates the secretion of oestrogen, brings 
about maturation of the ovum and causes ovulation. 
 LH stimulates the completion of the reduction division of the oocyte. 
Following ovulation, it produces luteinisation of the granulosa and the 
theca cells and initiates progesterone secretion. The LH surge precedes 
ovulation by 24 to 36 hours. 
 The hypothalamus is controlled by higher cortical centres especially 
temporal lobe. Emotional upsets stimulate or depress the H-P-O axis 
and disturb the menstrual cycle
(53)
. 
 
4.OESTROGEN: 
 The main sources of oestrogen are the theca and granulosa cells of the 
graffian follicles and corpus luteum, while the adrenal cortex is the 
secondary source. 
 Its level increase 6 to 7 days before ovulation and reaches the peak 2 
days before ovulation and then declines. 
 It increases uterine vascularityand regenerate the endometrium after 
menstruation and is responsible for the proliferative hyperplasia of the 
endometrium. 
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5.PROGESTERONE: 
 The corpus luteum is the main source of progesterone. The level rises 
after ovulation and reaches peak at mid luteal phase. With the 
degeneration of the corpus luteum, its level falls and brings about 
menstruation. 
 In an anovulatory cycle, progesterone is absent or present in negligible 
amount and the menstruation is brought by the fall in oestrogen level. 
 If pregnancy occurs the corpus luteum continues to enlarge and secrete 
progesterone. The high level of the hormone prevents menstruation 
and leads to amenorrhoea of pregnancy
(54)
. 
 
6.INHIBIN: 
 Inhibin is a peptide secreted by the graffian follicle and suppress 
pituitary FSH. In normal folliculogenesis FSH and LH initiate the 
secretion of oestrogen by the graffian follicles. Oestrogen is 
responsible for the secretion of inhibin in the graffian follicles, which 
in turn suppress FSH but stimulates LH. 
 In polycystic ovarian disease, there is increased secretion of inhibin. 
This causes a low FSH and LH secretion by pituitary resulting in 
anovulation. 
 
7.TESTOSTERONE: 
 The ovarian stromal cells secrete androgenic products, namely 
Testosterone, Dihydroepiandrosterone (DHEA) and Androstenedione. 
 Androstenedione gets converted to oestrogen in the peripheral fat. The 
increase in ovarian stroma is responsible for the rise in these hormones 
and development of hirsutism
(55)
. 
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POLY CYSTIC OVARIAN SYNDROME 
 
HISTORY: 
 In 1935 – Stein &Leventhal first described poly cystic ovarian 
syndrome. 
 In late 1960 and early 1970 deranged hypothalamic-pituitary axis is 
described. 
 In 1980 late complications related to insulin resistance. 
 By 1980 the use of ultrasound scans, the characterised polycystic 
appearance was recognized. 
 
PREVALENCE: 
 75% of hirsute women with normal menses but anovulatory cycles. 
 40% of hirsute women with normal ovulatory cycles(mildform of 
PCOS). 
 20% of normal women have mild form of PCOS. 
 4-7% of female in reproductive age has clinically evident PCOS. 
 The prevalence of PCOS depends on the choice of diagnostic criteria. 
The World Health Organisation estimates that it affects 116 million 
women worldwide as of 2010 (3.4% of the people). 
 One community based prevalence study using the Rotterdam criteria 
found that about 18% of women had PCOS and that 70% of them were 
previously undiagnosed. 
 
NOMENCLATURE: 
 Poly cystic ovary disease 
 Stein- Leventhal syndrome 
 Functional ovarian hyperandrogenism 
 Ovarian hyperthecosis 
 Sclero cystic ovary syndrome 
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DEFINITION: 
Thetwo definitions commonly used are, 
 
Definition 1: (1990) if a female patient has all the following, 
 Oligomenorrhoea 
 Signs of androgen excess 
 Other entities causing poly cystic ovaries are excluded 
 
Definition 2 :(2003) Rotterdam indicated pcos to be present if 2 out of 3 criteria are 
met 
 Oligomenorrhoea 
 Anovulation 
 Poly cystic ovaries ( ultra sound) 
 Hyperandrogenism(56) 
 
(2006) Rotterdam criteria: A women must have the two of the following three 
manifestations:      
 Excess androgen activity 
 Anovulation 
 Polycystic ovaries 
 Exclusion of other entities 
 
     While there are a number of definitions of PCOS, the Rotterdam consensus is the 
most widely accepted. The Rotterdam criteria require the presence of two of the 
following:  
 Oligo/ Anovulation 
 Hyperandrogenism- clinical or biochemical 
 Polycystic ovaries on ultrasound(57) 
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AETIO PATHOGENESIS: 
  There is disagreement and uncertainty as to what causes polycystic ovarian 
disease. Poly cystic ovaries and polycystic ovary syndrome have been associated with 
one or more of these factors:  
 Genetic predisposition 
 Insulin resistance or hyperinsulinism (high blood levels of insulin) 
 Obesity 
 Hyperandrogenism (excessive production of male hormones) 
 Abnormality of the hypothalamic-pituitary-gonadal axis ( organ / 
hormonal disorder) 
 Environmental chemical pollution ( hormonal disruptors) 
 Food adulteration (excitatory amino acids, for example) 
 Chronic inflammation 
 
Some of these causal factors may also be consequences of polycystic ovary 
disease. In other words, we have an amazingly complex network of interacting 
variables, each of which influences the other. Polycystic ovarian syndrome is not a 
simple disease with a single cause.   
 
PATHOGENISIS: 
    Exact pathophysiology of PCOS is not clearly understood. It may be discussed 
under the following    
 Over secretion of LHRH in hypothalamus causes increased secretion of 
the LH by the pituitary gland. The LH stimulates the ovarian stroma to 
secrete androstenodione which is converted to estrone in the fatty tissue. 
 The excess of estrone suppresses the secretion of FSH and sensitizes the 
pituitary to LHRH, increasing the secretion of LH. 
 I nhibin F – a poly peptide secreted by the granulosa cells in the ovaries 
may reduce further the secretion of FSH. 
 The increase in the ratio of LH and FSH in the plasma is the 
characteristic feature of pcod. The imbalances between the LH & FSH 
become self perpetuating. 
 Androstenedione is also converted to testosterone but the concentration 
of testosterone in the plasma usually remains high in normal range. 
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 The secretion of oestrogen by ovaries is reduced. 
 Obesity is common in the patients with the endocrine imbalance because 
the adipose tissue possesses aromatase enzyme that converts 
androstenedione to estrone and testosterone to etradiol. 
 Excess of adipose tissue creates both excess androgens ( responsible for 
hirsutism and virilisation) and excess oestrogen (inhibits FSH by 
negative feedback). 
 Hyper insulinaemia increase GnRH pulse frequency, LH over FSH 
dominance and increased ovarian androgen production. The elevated 
insulin levels also act on liver to inhibit production of sex hormone 
binding (SHBH) which leads to an increase in free testosterone. 
 Insulin resistance is a common finding among patients of normal weight 
as well as those overweight patients. 
 Insulin like growth factor 1 binding protein is reduced which leads to 
increased circulating insulin like growth factor 1 enhancing ovarian 
androgen production. 
 Some women may also have increased adrenal androgenic production. 
 All these leads to the decreased follicular maturation and anovulation 
which is the most common cause of infertility
(58)
. 
 
SIGNS AND SYMPTOMS: 
Some combination of the following symptoms that vary with each individual: 
 Multiple ovarian cysts 
 Irregular or absent menses 
 Infertility 
 Acne 
 Obesity or inability to lose weight 
 Excessive body or facial hair (hirsutism) 
 Insulin resistance and possibly diabetes 
 Thinning of scalp hair 
 Velvety, hyperpigmented skin folds (acanthosisnigricans) 
 High blood pressure 
 Polycystic ovaries that is 2-5 times larger than healthy ovaries 
 Sleep apnea 
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 Disordered immune system 
 Mood disorders, including anxiety and depression 
 Appetite disorder 
 High blood fats (cholesterol and triglycerides) 
 Increased probability of cardiovascular disease or diabetes 
 Multiple hormone imbalances, commonly including: 
 Androgens (testosterone) 
 Oestrogen 
 Progesterone 
 Prolactin 
 FSH (follicle stimulating hormone) 
 LH (luteinizing hormone) 
 Cortisol 
 Insulin 
 Thyroid hormone 
 
COMPLICATIONS: 
         Women with PCOS are at risk for the following, 
 Endometrial hyperplasia and endometrial carcinoma 
              Possibly due to over accumulation of the uterine lining and also lack of 
progesterone resulting in prolonged stimulation of uterine cells by oestrogen and 
also may be due to obesity, hyperinsulinaemia and hyper androgenism. 
 
 Hyper Insulinaemia 
High fasting and post prandial insulin level Peripheral insulin 
resistance. 
 
 Type 2 diabetes mellitus  
 Dyslipidaemia 
Disorder of lipid metabolism, cholesterol and triglycerides. PCOS patients 
show decreased removal of atherosclerosis inducing remnants. 
 
 Cerebro and cardio vascular diseases 
                Hypertension 
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                Endothelial dysfunction and impaired fibrinolysis (Circulating 
plasminogen activating factors level )  associated with the  risk  for vascular 
lesions like ischaemic heart disease and stroke. 
 
 Infertility 
      The chronic elevation of  insulin levels and enhanced ovarian sensitivity to 
insulin combined with elevated LH concentration results in ovarian thecal 
hyperplasia, increased androgen secretion, arrested follicular development and 
anovulation resulting in menstrual disturbance and infertility. 
 
 Miscarriage 
               This may be due to lack of progesterone. 
 
 Acanthosisnigricans 
Patches of darkened skin under the arms, in the groin area and on the back 
of the neck. 
 
 Auto immune thyroiditis 
 
DIAGNOSIS: 
               The diagnosis is made using the Rotterdam criteria, even when the 
syndrome is associated with a wide range of symptoms. 
 
STANDARD DIAGNOSTIC ASSESSMENTS: 
HISTORY TAKING: 
 Specifically for menstrual pattern, obesity, hirsutism and absence of breast 
discharge. 
 These four questions can diagnosis PCOS with a sensitivity of 77.1% and 
specificity of 93.8%. 
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GYNAECOLOGICAL ULTRASONOGRAPHY: 
 Looking for peripherally placed small ovarian follicles of size 5-7 mm 
giving the appearance of string of pearls and increased size of the ovaries 
that is 1.5 to 3 times larger than the normal. 
 
LAPROSCOPIC EXAMINATION: 
 This reveals a thickened smooth pearl white outer surface of the ovary. 
 
COMMON ASSESSMENT FOR ASSOCIATED CONDITIONS OR RISKS: 
 Fasting blood glucose and lipid profile. 
 2 hour oral glucose tolerance test (GTT) in patients with risk factor ( 
obesity , family history, H/O gestational diabetes) and may indicate 
impaired GTT in 15% - 30% women with PCOS. 
 Frank diabetes can be seen in 65% - 68% of women with this condition. 
 Insulin resistance can be observed in both normal weight and overweight 
patients. 
 Fasting insulin level to predict the response to medication. 
 
THE EXCLUSION OF OTHER DISORDERS: 
 Prolactin to rule out hyper prolactinaemia. 
 TSH to rule out Hypothyroidism. 
 17-hydroxy progesterone to rule out congenital Adrenal hyperplasia. 
 
DIFFERENTIAL DIAGNOSIS: 
Other causes of irregular or absent menstruation and hirsutism are, 
 Adrenal hyperplasia 
 Cushing’s syndrome  
 Hyper prolactinemia 
 Androgen secreting neoplasms 
 Other pituitary and adrenal disorder 
 Other insulin resistant situations such as acromegaly(59)(60).  
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                      LITERATURE REVIEW OF TRIAL MEDICINE 
                                       KALINGATHI ENNAI 
 
Reference: Sikitcharatna Deepam Irandam Pagamagiya Vaithiya Chinthamani    
Ingredients 
 Varithumatikai saru (Citrullus colcocynthis) 
 Vengaya saru (Allium cepa) 
 Elumitcham palasaru (Citrus limon) 
 Chitramanakku  ennai (Castor oil)  
 Inji rasam (Zingiber officinale)  
 Seeragam (Cuminum cyminum)   
 Dhaniya (Coriandrum sativum) 
 Sathakuppai (Anethum graveolens) 
 Lavangam (Syzygium aromaticum)  
 Lavangapattai (Cinnamomum verum) 
 Manjal (Curcuma longa)  
 Elam (Elettaria cardamomum) 
 
Standard Operating Procedure 
Source of raw drugs: 
          The required raw drugs are procured from a well reputed indigenous raw drug 
shop.  
Purification of  Siddha Drugs: 
            Siddha drugs are purified as mentioned in Sikitcha ratna deepam ennum 
vaidhiya nool. 
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Preparation: 
            The above mentioned juices and oil are mixed together in a mud pot and 
boiled. During boiling the above given purified herbal ingredients are made into 
powder form and mixed together. Finally, oil prepared in the way as mentioned in the 
literature is safely kept. 
Drug Storage: 
             The trial medicine is stored in a clean air tight dry container and it is 
dispensed medicament in a labeled container. 
Dosage: 
15ml once a day 
Adjuvant: 
             Warm water 
Duration: 
              Five days, Three consecutive menstrual cycles
(61)
. 
 
PROPERTIES OF TRIAL MEDICINE: 
1.VARITHUMATIKAI (fig 2.1)  
Synonyms  :    Aatruthumati, Kalingam 
Botanical name        :     Citrullus colcocynthis 
Suvai               :     Kaippu 
Thanmai            :     Veppam 
Pirivu             :     Kaarppu                  
Action                        :     Alterative 
                 Hydragogue    
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             Gastrointestinal irritant  
                     Emetic 
General characters : 
                                                     
                                       -          
                                                  
                                       (62).  
      
2.VENGAYAM (fig 2.2) 
Synonyms   :    Erulli, Pallandu 
Botanical name         :   Allium cepa 
Suvai   :    Kaippu 
Thanmai  :    Veppam 
Pirivu   :    Kaarppu 
Action              :    Emmenagogue 
                  Demulcent 
                 Stimulant 
General characters:   
                                           
                                     -      
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                                   (63).  
   
3.ELUMITCHAI (fig 2.3) 
Synonyms           :   Sambeeram 
Botanical name       :   Citrus limon 
Suvai            :   Pulippu 
Thanmai           :   Veppam 
Pirivu            :   Kaarppu 
Action            :   Refrigerant 
General charactres:   
                                           
                                   -         
                                                
                                  (64). 
 
4.CHITRAMANAKKU  (fig 2.4) 
Synonyms  :     Yerandam,Chithiram 
Botanical name         :     Ricinus communis 
Suvai   :     Kaippu 
Thanmai  :     Veppam 
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Pirivu   :     Kaarppu 
Action              :     Anti-vata 
                   Galactagogue 
                    Laxative 
 
General characters :    
                                           
                                -         
                                          
                                (65). 
      
5. INJI  (fig 2.5) 
Synonyms       :   Allam, Arthragam 
Botanical name   :       Zingiber officinale 
Suvai        :     Kaarppu 
Thanmai       :   Veppam 
Pirivu        :   Kaarppu 
Action        :    Stimulant 
               Carminative 
               Stomachic 
                                      Digestive 
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General characters :   
                                      
                               -       
                                       
                           –    (66). 
      
6.SEERAGAM (fig 2.6) 
Synonyms        :  Asai, Bosanakudari 
Botanical name    :     Cuminum cyminum 
Suvai         :    Kaarppu, Inippu 
Thanmai               :    Thatpam 
Pirivu         :    Inippu 
Action         :   Carminative 
             Stimulant 
              Astringent 
                                    Stomachic 
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General characters:       
                                           
                                   –       
                               !              
                               (67).  
      
7. DHANIYA  (fig 2.7) 
Synonyms          :           Kothumalli, Urularisi 
Botanical name      :            Coriandrum sativum 
Suvai           :           Kaarppu 
Thanmai          :           Seedhaveppam 
Pirivu           :           Kaarppu 
Action           :           Carminative 
                      Stomachic 
                      Stimulant 
General characters:  
                                               
                                       -        
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                                   (68).    
 
8.SATHAKUPPAI (fig 2.8) 
Synonyms   : Madhurigai 
Botanical name                     :           Anethum graveolens  
Suvai    :          Inippu 
Thanmai   :  Veppam 
Pirivu    :  Kaarppu 
Action              :  Emmenagogue 
                        Stimulant 
                         Stomachic 
                                                           Carminative 
                                                           Antispasmodic 
General characters :   
                                     
                                      -      
                                    
                             (69). 
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9.LAVANGAM (fig 2.9) 
Synonyms  :       Anjugam, Urkadam 
Botanical name         :       Syzygium aromaticum 
Suvai                :       Kaaramum viruvirupumulathu  
Thanmai             :       Veppam 
Pirivu   :       Kaarppu 
Action              :       Carminative 
                                            Antispasmodic 
                     Stomachic 
General characters: 
                                           
                                      -     
                                         
                                 . 
                                            
                                   -       
                                         
                              (70). 
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10.LAVANGAPATTAI (fig 2.10) 
Synonyms  :        Karuvapattai 
Botanical name         :         Cinnamomum verum  
Suvai   :         Kaaramum inippum 
Thanmai  :         Thatpham 
Pirivu   :         Inippu 
Action              :         Stimulant 
                       Carminative 
                       Aphrodisiac 
General characters:  
                                          
                                 -       
                                          
                          . 
                                              
                                   -       
                                          
                          !    (71).  
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11.MANJAL (fig 2.11) 
Synonyms  : Arisinam, Nisi 
Botanical name         :          Curcuma longa 
Suvai              :          Kaarppu, Kaippu 
Thanmai  : Veppam  
Pirivu   :          Kaarppu  
Action   : Carminative 
                                               Stimulant 
General characters: 
                                           
                            -        
                                              
                             (72). 
                        
 12.ELAM (fig 2.12) 
Synonyms  :  Aanji, Korangam 
Botanical name         :          Elettaria cardamomum 
Suvai              : Kaarppu 
Thanmai  :          Veppam 
Pirivu   :          Kaarppu 
Action              :          Carminative 
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                        Stimulant 
                        Stomachic 
General characters: 
                                       
                                                     
                                       
                                             
                                         
                                               
                                        
                                ஏ        …(73)   
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             Fig 2.1 VARITHUMATIKAI                            Fig 2.2 VENGAYAM 
 
 
                
      Fig 2.3 ELUMITCHAI                                  Fig 2.4 CHITRAMANAKKU ENNAI 
 
 
                  
                 Fig 2.5 INJI                                             Fig 2.6 SEERAGAM 
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               Fig 2.7 DHANIYA                                   Fig 2.8 SATHAKUPPAI       
 
 
             
            Fig 2.9 LAVANGAM                            Fig 2.10 LAVANGAPATTAI 
 
 
 
              
              Fig 2.11 MANJAL                                         Fig 2.12 ELAM 
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 MATERIALS AND METHODS 
 
EXPERIMENTAL STUDY DESIGN 
           This prospective, observational open clinical trial was performed on PCOS 
patients at one centres affiliated with The Tamil Nadu Dr. M.G.R. Medical 
University, Chennai between  2016-2018. 
            
The study was conducted in the department of medicine, Arignar Anna 
Hospital of Indian Medicine, Chennai and with the assistance of laboratory setup of 
the department of biochemistry, AAHIM, Chennai. All subjects were being 
considered for the treatment with trial drug. 
 
The study was approved by Institutional Ethics Committee (IEC) and the 
approved number is GSMC-CH-ME-5/002/2016. The study was registered in Clinical 
Trials Registry India (CTRI) and the reference number is REF/2018/02/017330. 
 
SELECTION OF SAMPLE SIZE 
           40 female patients in the age group 15-45 years. 
 
SELECTED CRITERIA 
INCLUSION CRITERIA: 
          Patients with the following criteria are included in the study 
 Polycystic ovaries on ultrasound examination 
 Irregular menstruation 
 Dysmenorrhea 
 Ovulation related infertility 
 Oligomenorrhoea 
 Hirsutism 
 Acanthosis nigricans 
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EXCLUSION CRITERIA 
           Patients with the following criteria are excluded from the study 
 Hemorrhagic cyst 
 Chocolate cyst 
 Endometriosis 
 Pituitary / Adrenal disorders 
 Tuberculosis of the ovary and uterus 
 Congenital uterine defects 
 Hyperthyroidism / Hypothyroidism 
 
WITHDRAWAL CRITERIA 
Patients who have not completed the trial period are withdrawn from the 
study. 
 
EVALUATION OF CLINICAL PARAMETERS 
Patients are clinically evaluated by the following parameters 
 
HISTORY TAKING 
Age, occupation, socio-economic status, complaints and its duration, 
menstrual history, marital history, family history, previous illness, personal habits, 
body mass index were recorded in the case sheet for every patient at the time of first 
visit to the op. 
INVESTIGATIONS 
All patients were subjected to the laboratory investigations before and after the 
treatment. 
BLOOD CHEMISTRY 
           TC, DC, ESR, HB, 
           Blood Sugar ( R ) 
           Serum Cholesterol 
 
URINE ANALYSIS 
          Albumin, Sugar, Deposits 
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RADIOGRAPHICAL FINDINGS OF ULTRASONOGRAM 
 Whole abdomen and pelvis 
 Follicular study 
 
CLINICAL DIAGNOSIS BASED ON SIDDHA SYSTEM OF MEDICINE 
          The parameters used to diagnosis Soothaga vaayu based on Siddha system 
 Poriyaalarithal 
 Pulanaalarithal 
 Vinathal 
 Envagaithervugal 
 Uyirthathukkal 
 Udalthathukkal 
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                                  RESULTS AND OBSERVATION 
         The study on Soothaga vaayu was carried out with 40 patients in the Out Patient 
Department, PG Maruthuvam, Govt Siddha Medical College attached to AAGHIM, 
Chennai-106, during the year 2016-2018 were analysed. 
The observations were made and tabulated regarding the following criteria: 
1. Age distribution 
2. Distribution of Kaalam 
3. Occupation ( Nature of work ) 
4. Socio-economic status 
5. Food habits  
6. Marital status 
7. Body mass index 
8. Paruvakaalam 
9. Thinai 
10. Distribution of vatham   
11. Distribution of pitham 
12. Distribution of kabham 
13. Defects in udal thathukkal 
14. Envagai thervugal 
15. Naadi 
16. Neikuri 
17. Signs and symptoms before and after treatment  
18. Result 
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1. AGE DISTRIBUTION 
AGE 
(YEARS) 
NO OF CASES PERCENTAGE (%) 
15-20 years 10 25% 
21-25 years 13 32.5% 
26-30 years 10 25% 
31-35 years 5 12.5% 
36-40 years 2 5% 
 
 
 
 
INFERENCE: 
               25% of patients were in the age group 15-20, 32.5% of patients were in the 
age group 21-25, 25% of patients were in the age group 26-30, 12.5% of patients were 
in the age group 31-35 and 5% of patients were in the age group 36-40. 
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2. DISTRIBUTION OF KAALAM 
KAALAM NO. OF CASES PERCENTAGE 
Vatha kaalam (0-33) 38 95% 
Pitha kaalam (34-66) 2 5% 
Kaabha kaalam (66-100) 0 0 
 
 
 
 
 
INFERENCE: 
                95% of patients were in vatha kaalam and 5%  of patients were in pitha 
kaalam.   
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3. OCCUPATION (NATURE OF WORK ) 
WORK NO.OFCASES PERCENTAGE (%)   
Student 18 45% 
Working women 12 30% 
House wife 10 25% 
 
 
 
 
 
 
INFERENCE: 
                45% of patients were students, 30% of patients were working women and 
25% of patients were house wife.  
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4. SOCIO ECONOMIC STATUS 
SOCIOECONOMIC STATUS NO.OF CASES PERCENTAGE 
(%) 
Low income (Below 2,00,000 perannum) 9 22.5% 
Middle income (below 5,00,000 perannum) 17 42.5% 
High income (above 5,00,000perannum) 14 35% 
 
 
 
 
 
INFERENCE: 
                22.5% of patients were from low income group, 42.5% of patients were 
from middle income group, 35% of patients were from high income group.   
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5. FOOD HABITS 
DIET NO.OF CASES PERCENTAGE (%)  
Vegetarian 8 20% 
Mixed diet 32 80% 
 
 
 
             
 
 
INFERENCE: 
                80% of patients belong to mixed diet and 15% of patients belong to 
vegetarian diet habit. 
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 6. MARITAL STATUS 
MARITAL STATUS NO.OF CASES PERCENTAGE (%) 
Married 19 47.5% 
Unmarried 21 52.5% 
 
 
 
         
 
 
 INFERENCE: 
                 47.5%  of patients were married and 52.5% of patients were unmarried.    
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7. BODY MASS INDEX 
BMI (kg/m
2
) NO. OF CASES PERCENTAGE (%) 
Normal (18.9 – 24.9) 23 57.5% 
Overweight (25 – 29.9) 16 40% 
Obese (30 – 34.9) 01 2.5% 
 
 
 
 
 
 
INFERENCE 
                57.50% of patients was normal (18.9-24.9 kg/m
2
), 40% of patients was 
overweight (25-29.9 kg/m
2
), and 2.5% of patient was obese (30-34.9 kg/m
2
). 
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8. PARUVAKAALAM 
KAALAM NO.OF CASES PERCENTAGE(%) 
Kaar kaalam (Aug 16- Oct 15) 0 0 
Koothir kaalam (Oct 16- Dec 15) 0 0 
Munpani kaalam (Dec 16- Feb 15) 18 45% 
Pinpani kaalam (Feb 16- Apr 15) 22 55% 
Elaveni kaalam (April 16- June 15) 0 0 
Muthuvenil kaalam (Jun 16- Aug 
15) 
0 0 
 
 
 
INFERENCE: 
                45% patients were reported in munpanikaalam and 55% patients were 
reported in pinpanikalam. 
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9.  DISTRIBUTION OF THINAI 
THINAI NO.OF CASES PERCENTAGE (%) 
Kurinji 0 0% 
Mullai 0 0% 
Marudham 0 0% 
Neithal 40 100% 
Paalai 0 0% 
 
 
 
 
INFERENCE: 
                100% of patients were from Neithal thinai. 
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10. DISTRIBUTION OF VATHAM 
VATHAM NO.OF CASES PERCENTAGE (%) 
Pranan 0 0% 
Abanan 40 100% 
Udanan 0 0 
Vyanan 27 67.5% 
Samanan 10 25% 
Naagan 0 0% 
Koorman 0 0% 
Kirugaran 0 0% 
Devadhathan 15 37.5% 
Thananjeyan 0 0 
 
 
 
INFERENCE: 
                Abanan affected in 100% patients, Vyanan affected in 67.5% patients, 
Samanan affected in 25% patients, Devedhathan affected in 37.5% patients. 
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11. DISTRIBUTION OF PITHAM 
PITHAM NO.OF CASES PERCENTAGE (%) 
Analagam 10 25% 
Ranjagam 10 25% 
Sathagam 40 100% 
Prasagam 13 32.5% 
Aalosagam 0 0% 
 
 
 
 
INFERENCE: 
                Analagam affected in 25% of  patients, Ranjagam affected in 25% of 
patients, Sathagam affected in 100% patients and Prasagam affected in 32.5% of 
patients.   
 
 
25% 25% 
100% 
32.50% 
0% 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Analagam Ranjagam Sathagam Prasagam Aalosagam
DISTRIBUTION OF PITHAM 
DISTRIBUTION OF PITHAM
                                                                            RESULTS AND OBSERVATION 
 
 Page 84 
 
12. DISTRIBUTION OF KABHAM 
KABHAM NO.OF CASES PERCENTAGE (%)  
Avalambagam 0 0% 
Kilethagam 10 25% 
Pothagam 0 0% 
Tharpagam 0 0% 
Santhigam 15 37.5% 
  
 
 
 
INFERENCE: 
                Santhigam was affected in 37.5% of patients and Kilethagam was affected 
in 25% of patients. 
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13. DISTRIBUTION OF UDAL THATHUKKAL 
THATHUKKAL NO.OF CASES PERCENTAGE (%)  
Saaram 40 100% 
Senneer 10 25% 
Oon 0 0% 
Kozhupu 0 0% 
Enbu 15 37.5% 
Moolai 0 0% 
Suronitham 40 100% 
 
 
 
INFERENCE: 
                Suronitham and Saram were affected in all patients 100%, Enbu was 
affected in 38% of patients and Senneer was affected in 25% of patients.  
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14. ENVAGAI THERVUGAL 
ENVAGAI 
THERVUGAL 
NO.OF CASES PERCENTAGE (%) 
Naa 10 25% 
Niram 13 32.5% 
Mozhi 0 0% 
Vizhi 10 25% 
Sparisam 0 0% 
Malam 16 40% 
Moothiram 0 0% 
Naadi 40 100% 
 
 
 
INFERENCE: 
                Naa affected in 25% of patients, Niram affected in 32.5% of patients, Vizhi 
affected in 25% of patients, Malam affected in 40% of patients, Naadi affected in 
100% of patients.  
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  15. DISTRIBUTION OF NAADI 
NAADI NO.OF CASES PERCENTAGE (%) 
Vatha pitham 27 67.5% 
Pitha vatham 12 30% 
Kabha pitham 1 2.5% 
 
 
 
 
 
INFERENCE: 
                67.5% of patients had Vatha pitha Naadi, 30% of patients had Pitha vatha 
Naadi and 2.5% of patients had Kabha pitha Naadi. 
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16. NEIKURI 
NEIKURI NO.OF CASES PERCENTAGE (%) 
Vatham (snake like) 28 70% 
Pitham (ring like) 10 25% 
Kabham (pearl like) 02 5% 
 
 
 
 
 
INFERENCE: 
               70% of patients had Vatha neer, 25% of patients had Pitha neer and 5% of 
patients had Kabha neer. 
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17. CLINICAL MANIFESTATIONS 
SIGNS & 
SYMPTOMS 
BEFORE TREATMENT AFTER TREATMENT 
NO.OF 
PATIENTS 
PERCENTAGE
(%) 
NO.OF 
PATIENTS 
PERCENTAGE 
(%) 
Irregular 
menstruation 
40 100% 10 25% 
Oligo menorrhoea 26 65% 2 5% 
Dysmenorrhoea 20 50% 2 5% 
Infertility 4 10% 2 5% 
Hirsutism 6 15% 4 10% 
Acanthosis 
Nigricans 
10 25% 8 20% 
 
 
INFERENCE: 
                75% of patients were relived from irregular menstruation, 60% of patients 
were relieved from oligomenorrhoea, 45% of patients were relieved from 
dysmenorrhoea, 5% of patients were relived from hirsutism, 5% of patients were 
relieved from A.nigricans and 5% were conceived.  
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18.RESULT 
RESULT NO.OF CASES PERCENTAGE (%) 
Good 27 67.5% 
Moderate 08 20% 
Poor 05 12.5% 
 
 
 
 
INFERENCE: 
                Out of 40 cases 27 (67.5%) had good result, 8 cases (20%) had moderate 
result and 5 cases (12.5%) had poor result. 
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        RESULTS OF PATIENTS BEFORE AND AFTER TREATMENT 
                                      ULTRASONOGRAM REPORT 
Sl.NO OP 
NO 
AGE/ 
SEX 
DURATION 
OF 
CYCLES 
OVARY 
VOLUME 
BT 
OVARY 
VOLUME  
            AT 
1. 5052 21 3 RT - 12ml 
LT – 13ml 
RT – 8ml 
LT – 6ml 
2. 5090 24 3 RT – 16ml 
LT – 21ml 
Both ovaries 
appear normal in 
size  
3. 8765 32 3 RT – 9ml 
LT – 12ml 
RT – 5ml 
LT – 6ml 
4. 9138 22 3 RT – 30ml 
LT – 29ml 
RT – 30ml 
LT – 28ml 
5. 770 36 3 RT – 7ml 
LT – 9ml 
RT – 6ml 
LT – 7ml 
6. 787 17 3 RT – 14ml 
LT – 10ml 
RT – 10ml  
LT – 6ml 
7. 1022 18 3 RT – 14ml 
LT – 3ml 
RT – 5ml 
LT – 6ml 
8. 1522 21 3 RT – 20ml 
LT – 21ml 
RT – 10ml 
LT – 12ml 
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9. 1840 33 3 RT – 12ml 
LT – 8ml 
RT – 7ml 
LT – 5ml 
10. 4670 20 3 RT – 30ml 
LT – 13ml 
RT – 30ml 
LT – 13ml 
11. 8555 29 3 RT – 37ml 
LT – 38ml 
RT – 36ml 
LT – 37ml 
12. 8763 32 3 RT – 23ml 
LT – 19ml 
RT – 23ml 
LT – 18ml 
13. 8818 20 3 RT – 13ml 
LT – 6ml 
Both ovaries appear 
normal in size 
14. 8900 19 3 RT – 10ml 
LT – 7ml 
RT – 7ml 
LT – 5ml 
15. 9012 25 3 RT – 10ml 
LT – 9ml 
RT – 6ml 
LT – 7ml 
16. 9765 27 3 RT – 9ml 
LT – 9ml 
RT – 6ml 
LT – 5ml 
17. 149 23 3 RT – 14ml 
LT – 13ml 
RT – 15ml 
LT – 14ml 
18. 325 24 3 RT – 12ml 
LT – 18ml 
RT – 6ml 
LT – 7ml 
19. 521 32 3 RT – 6ml 
LT – 11ml 
RT – 5ml 
LT – 5ml 
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20. 1623 20 3 RT – 7ml 
LT – 6ml 
RT – 6ml 
LT – 5ml 
21. 1626 26 3 RT – 7ml 
LT – 5ml 
RT – 6ml 
LT – 7ml 
22. 1631 21 3 RT – 12ml 
LT -  15ml 
RT – 12ml 
LT – 16ml 
23. 1646 24 3 RT – 15ml 
LT – 21ml 
RT – 12ml 
LT – 10ml 
24. 2929 28 3 RT – 22ml 
LT – 16ml 
RT – 22ml 
LT – 16ml 
25. 3510 19 3 RT – 7ml 
LT – 9ml 
RT – 6ml 
LT – 9ml 
26. 3703 21 3 RT – 6ml 
LT – 4ml 
RT – 5ml 
LT – 6ml 
27. 4810 20 3 RT – 22ml 
LT – 18ml 
RT – 10ml 
LT – 12ml 
28. 5015 26 3 RT – 8ml 
LT – 7ml 
RT – 6ml 
LT – 5ml 
29. 5514 15 3 RT – 10ml 
LT – 9ml 
RT – 9ml 
LT – 7ml 
30. 5739 21 3 RT – 24ml 
LT – 19ml 
RT – 24ml 
LT – 19ml 
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31. 5842 29 3 RT – 16ml 
LT – 7ml 
RT – 16ml 
LT – 6ml 
32. 8874 27 3 RT – 10ml 
LT – 8ml 
RT – 5ml 
LT – 8ml 
33. 8980 25 3 RT – 18ml 
LT – 14ml 
RT – 18ml 
LT – 14ml 
34. 9970 32 3 RT – 19ml 
LT – 23ml 
RT – 13ml 
LT – 18ml 
35. 341 26 3 RT – 20ml 
LT – 21ml 
RT – 12ml 
LT – 16ml 
36. 1298 34 3 RT – 10ml 
LT – 16ml 
RT – 10ml 
LT – 16ml 
37. 1462 38 3 RT – 8ml 
LT – 6ml 
RT – 8ml 
LT – 4ml 
38. 1488 30 3 RT – 11ml 
LT – 16ml 
RT – 12ml 
LT – 15ml 
39. 1537 22 3 RT – 10ml 
LT – 7ml 
RT – 10ml 
LT – 7ml 
40. 1592 15 3 RT – 10ml 
LT – 9ml 
RT – 11ml 
LT – 8ml 
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                                     FOLLICULAR STUDY REPORT 
 
Sl.NO OP NO AGE / 
SEX 
FOLLICULAR 
STUDY 
            BT           
FOLLICULAR 
STUDY     
             AT 
REMARKS 
1. 5052 21 Anovulatory cycle Dominant follicle 
seen 
Completed 
2. 5090 24 Anovulatory cycle Dominant follicle 
seen 
Completed 
3. 8765 32 Anovulatory cycle Dominant follicle 
seen 
Completed 
4. 9138 22 Anovulatory cycle No dominant 
follicles 
Symptoms 
reduced 
5. 770 36 Anovulatory cycle Dominant follicle 
seen 
Completed 
6. 787 17 Anovulatory cycle Dominant follicle 
seen 
Completed 
7. 1022 18 Anovulatory cycle Dominant follicle 
seen 
Completed 
8. 1522 21 Anovulatory cycle Dominant follicle 
seen 
Completed 
9. 1840 33 Anovulatory cycle Dominant follicle 
seen 
Completed 
10. 4670 20 Anovulatory cycle No dominant 
follicles 
No changes 
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11. 8555 29 Anovulatory cycle No dominant 
follicles 
Symptoms 
reduced 
12. 8763 32 Anovulatory cycle No dominant 
follicles 
Symptoms 
reduced 
13. 8818 20 Anovulatory cycle Dominant follicle 
seen 
Completed 
14. 8900 19 Anovulatory cycle Dominant follicle 
seen 
Completed 
15. 9012 25 Anovulatory cycle Dominant follicle 
seen 
Completed 
16. 9765 27 Anovulatory cycle Dominant follicle 
seen 
Completed 
17. 149 23 Anovulatory cycle No dominant 
follicles 
Symptoms 
reduced 
18. 325 24 Anovulatory cycle Dominant follicle 
seen 
Completed 
19. 521 32 Anovulatory cycle Dominant follicle 
seen 
Completed 
20. 1623 20 Anovulatory cycle Dominant follicle 
seen 
Completed 
21. 1626 26 Anovulatory cycle Dominant follicle 
seen 
Completed 
22. 1631 21 Anovulatory 
cycle 
No dominant 
follicles 
Symptoms 
reduced 
23. 1646 24 Anovulatory cycle Dominant follicle Completed 
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seen 
24. 2929 28 Anovulatory cycle No dominant 
follicles 
No changes 
25. 3510 19 Anovulatory cycle Dominant follicle 
seen 
Completed 
26. 3703 21 Anovulatory cycle Dominant follicle 
seen 
Completed 
27. 4810 20 Anovulatory cycle Dominant follicle 
seen 
Completed 
28. 5015 26 Anovulatory cycle Dominant follicle 
seen 
Completed 
29. 5514 15 Anovulatory cycle Dominant follicle 
seen 
Completed 
30. 5739 21 Anovulatory cycle No dominant 
follicles 
No changes 
31. 5842 29 Anovulatory cycle No dominant 
follicles 
Symptoms 
reduced 
32. 8874 27 Anovulatory cycle Dominant follicle 
seen 
Completed 
33. 8980 25 Anovulatory cycle No dominant 
follicles 
No changes 
34. 9970 32 Anovulatory cycle Dominant follicle 
seen 
Completed 
35. 341 26 Anovulatory cycle Dominant follicle 
seen 
Completed 
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36. 1298 34 Anovulatory cycle No dominant 
follicles 
No changes 
37. 1462 38 Anovulatory cycle Dominant follicle 
seen 
Completed 
38. 1488 30 Anovulatory cycle No dominant 
follicles 
Symptoms 
reduced 
39. 1537 22 Anovulatory cycle Dominant follicle 
seen 
Completed 
40. 1592 15 Anovulatory cycle No dominant 
follicles 
Symptoms 
reduced 
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                      BLOOD INVESTIGATION AND RESULTS 
SL 
NO 
OP 
NO 
BEFORE TREATMENT AFTER TREATMENT 
 
TC 
(cu/mm) 
DC ESR(mm) TC 
(cu/mm) 
DC ESR(mm) 
P% L% E% 1/2 1 P% L% E% 1/2 1 
1. 5052 9100 71 25 4 5 10 8900 62 32 6 10 16 
2. 5090 6400 67 32 1 7 15 7600 54 42 4 20 60 
3. 8765 10900 54 39 7 10 8 9800 64 35 1 4 8 
4. 9138 8900 59 38 3 12 25 9200 58 40 2 13 26 
5. 770 8100 60 33 7 30 65 8000 62 36 2 4 9 
6. 787 14500 81 16 3 30 70 14500 70 25 5 8 12 
7. 1022 10900 61 34 5 12 25 9800 60 34 6 4 9 
8. 1522 9300 65 30 5 14 29 8700 61 35 4 7 14 
9. 1840 8200 55 41 4 2 8 8300 68 32 0 4 9 
10. 4670 8200 60 36 4 5 12 9000 65 32 3 6 12 
11. 8555 9700 54 42 4 5 12 9800 64 35 1 4 8 
12. 8763 7600 59 39 2 7 14 8800 64 32 4 5 12 
13. 8818 7900 64 31 5 10 22 8200 63 35 2 4 9 
14. 8900 7800 59 37 4 8 12 8700 50 44 6 8 13 
15. 9012 9100 62 41 2 8 14 9700 60 38 2 6 9 
16. 9765 8000 56 39 5 15 28 8000 62 36 2 4 9 
17. 149 6900 55 40 5 22 40 7200 65 35 0 12 20 
18. 325 9000 51 45 4 5 13 9600 55 45 3 4 12 
19. 521 7400 56 41 3 6 12 8600 57 40 3 5 12 
20. 1623 9300 64 29 7 5 13 9600 55 42 3 4 12 
21. 1626 7800 59 38 3 5 12 8300 61 35 4 7 14 
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22. 1631 8700 65 31 4 20 48 7600 60 36 4 3 10 
23. 1646 6900 71 26 3 9 29 7000 64 35 1 9 18 
24. 2929 7800 56 40 4 10 22 6900 52 43 5 7 12 
25. 3510 10500 69 29 2 8 15 10600 57 40 3 8 20 
26. 3703 8100 58 37 5 25 56 8000 53 42 5 12 24 
27. 4810 8500 56 39 5 12 20 8700 65 30 5 5 9 
28 5015 9400 71 25 4 14 21 8500 68 27 5 16 26 
29. 5514 9000 72 24 4 6 12 9200 68 29 3 8 16 
30. 5739 6300 61 34 5 13 25 8300 52 42 6 10 20 
31. 5842 7600 50 44 6 2 7 8700 52 42 6 2 7 
32. 8874 8900 61 34 5 7 15 8800 62 36 2 4 9 
33. 8980 7500 67 31 2 18 40 7900 68 30 2 18 34 
34. 9970 10500 64 32 4 13 26 10200 52 40 8 18 28 
35. 341 6600 67 28 5 10 22 7500 72 26 2 6 11 
36. 1298 10500 61 33 6 36 25 10500 67 30 3 12 18 
37. 1462 8500 57 40 3 5 15 7800 56 41 3 5 12 
38. 1488 8700 62 36 2 5 12 8600 58 38 4 6 14 
39. 1537 7000 52 43 5 3 6 7700 58 38 4 4 10 
40. 1592 7300 54 36 10 14 26 7200 56 36 8 15 23 
 
TC : TOTAL COUNT 
DC: DIFFERENTIAL COUNT 
ESR: ERYTHROCYTE SEDIMENTATION RATE 
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SL 
NO 
OP 
NO 
BEFORE 
TREATMENT 
AFTER TREATMENT 
       URINE 
 
SU HB 
CHO
L 
SU HB CHOL A S D 
(mg/
dl) 
(%) 
(mg/d
l) 
(mg/dl) (%) (mg/dl)    
1. 5052 63 12.2 114 94 12.5 138 N N N 
2. 5090 90 10.4 165 115 10.2 130 N N N 
3. 8765 80 12.5 156 100 12.5 164 N N N 
4. 9138 81 11.6 120 112 11.4 119 N N N 
5. 770 98 9.7 152 110 10.2 150 N N N 
6. 787 101 10.4 130 106 11.1 152 N N N 
7. 1022 82 9.8 112 108 10.5 125 N N N 
8. 1522 82 12.1 184 90 12.5 172 N N N 
9. 1840 96 9.8 190 98 10 189 N N N 
10. 4670 98 11.2 189 100 11.4 190 N N N 
11. 8555 99 10.6 156 101 10.8 164 N N N 
12. 8763 120 10.2 117 121 10.2 123 N N N 
13. 8818 112 11.6 180 120 11.2 178 N N N 
14. 8900 77 8.4 160 120 11 156 N N N 
15. 9012 87 10.6 120 100 13.3 130 N N N 
16. 9765 80 11 152 110 11 150 N N N 
17. 149 120 11.1 156 110 10.8 145 N N N 
18. 325 98 12.8 198 112 12.9 194 N N N 
19. 521 89 12.1 160    92 12.1 140 N N N 
20. 1623 98 13.8 198   112 12.9 194 N N N 
21. 1626 82 10 184    90 11.1 190 N N N 
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SU: SUGAR                                                       A: ALBUMIN   
CHOL: CHOLESTEROL                                   S: SUGAR 
HB: HEMOGLOBIN                                          D: DEPOSIT           
22. 1631 110 12.1 152    91 12.1 155 N N N 
23. 1646 120 13.5 153 124 12.1 140 N N N 
24. 2929 83 10.1 185 110 12.9 194 N N N 
25. 3510 72 12.2 135 110 11.1 190 N N N 
26. 3703 88 13.4 170 90 12.1 155 N N N 
27. 4810 113 12.4 163 110 13.4 156 N N N 
28 5015 113 12 169 116 10.9 165 N N N 
29. 5514 104 8.2 162 112 13.2 140 N N N 
30. 5739 72 11.3 178 94 13.2 167 N N N 
31. 5842 107 10.4 174 107 12.6 150 N N N 
32. 8874 109 11.6 157 108 12.5 160 N N N 
33. 8980 115 10 120 110 9.5 158 N N N 
34. 9970 68 10.8 138 95 11.5 175 N N N 
35. 341 90 12.4 135 116 10.4 153 N N N 
36. 1298 79 11.0 147 112 11.4 158 N N N 
37. 1462 90 10.3 153 87 10.4 125 N N N 
38. 1488 90 12.8 136 104 11 135 N N N 
39. 1537 110 9.8 158 104 12.4 140 N N N 
40. 1592 102 10.5 156 106 11.6 153 N N N 
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   DISCUSSION 
           
SOOTHAGA VAAYU, one of the clinical entity described in 
Aathmaratchamirtham ennum vaidhiya sangiragam can be compared with Poly Cystic 
Ovarian Syndrome. The classical clinical features are Irregular menstruation, 
Dysmenorrhoea, Oligomenorrhoea, Hirsutism, Acanthosis nigricans, Infertility.   
   
POLYCYSTIC OVARIAN SYNDROME is one of the most common female 
endocrine disorder. It’s a complex, heterogenous disorder of uncertain aetiology. It 
affects 5-26% of women nowadays, like one in every three women especially in the 
reproductive age group affected by polycystic ovarian syndrome. 
         
It is the most common cause for infertility. But there is no complete and 
satisfactory relief from their symptoms by other systems of medicine. Hence with the 
help of trial medicine the study was conducted in Arignar Anna Government Hospital 
of Indian Medicine attached to Government Siddha Medical College, Arumbakkam, 
Chennai, Tamilnadu, India. Hence 40 female patients with Soothaga vaayu were 
selected. 
         
The Trial medicine KALINGATHI ENNAI was administered 15ml once a day 
with warm water before food for 5days for three consecutive menstrual cycles. 
         
With the help of trail medicine from Siddha system, results and observations 
are noted for this study. The patients were examined based on Siddha and as well as 
Modern aspects. 
        
All the necessary investigations were made during the study. The results 
obtained from their studies were discussed below for better conclusion. 
 
DRUG AUTHENTICATION: 
Authentication of given specimen is the basic starting point in developing a 
botanical product. 
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    A sample of specimen is collected from raw drug store and its Organoleptic 
characters, Microscopic and Macroscopic examination was conducted and 
authenticated by Botanist, CCRS, Chennai. 
 
PHYSIOCHEMICAL ANALYSIS: 
Physiochemical parameters include 
Loss on drying at 70
0
C   -  8.20 
Water soluble ash     -          8.75 
Acid insoluble ash     -          0.85 
Water soluble extractive value  -          7.20   
pH analysis      -          6.540 
    
These values of the given sample were compared with the standard values of 
Indian pharmacopeia. 
 
PHARMACOLOGICAL EVALUATION: 
The experimental protocol was approved by The Institutional Animal Ethics 
Committee of C.L. Baid Metha College of Pharmacy, Chennai, Tamil Nadu, India. 
          
  IAEC NO: LI/14/CLBMCP/2017. 
          
Pharmacological studies of the trial medicine Kalingathi Ennai showed 
OVULATION INDUCING ACTIVITY on tested animals. 
 
TOXICOLOGICAL STUDIES: 
           Acute and sub acute toxicity studies for Kalingathi ennai were conducted. 
 
           Acute toxicity study of Kalingathi ennai reveals no mortality, no abnormal 
signs and no behavioural changes in rat at the dose upto 200mg/kg body weight. 
 
           Sub acute oral toxicity study reveals no significant changes in the body weight, 
organ weight and biochemical parameters. 
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           The toxicological study results show that the trial medicine has no toxic effects 
and they are safe.      
 
BIOCHEMICAL ANALYSIS: 
Biochemical assays are needed to evaluate disease models and to drive 
biomarker analysis in translation medicine and clinical research. 
 
           Based on the analysis Kalingathi Ennai contains Reducing sugar. 
 
IEC: 
           IEC has approved my trial medicine with the allowed sample size of 40 
patients with combined gender. 
           IEC NO: GSMC-CH-ME-5/002/2016 
 
CTRI: 
The global mandate is to register all clinical trials prospectively, i.e. before the 
enrolment of the first patient. I have successfully registered my trial medicine by 
submitting the details and scientific data’s to Clinical Trial Registry. 
         
CTRI NO: CTRI/2018/03/012768 
 
CLINICAL STUDY: 
Clinical studies were conducted followed by CTRI registration with the 
sample size of 40 patients. 
 
In my study, 40 patients with Soothaga Vaayu were selected in the 
Department of Maruthuvam, Government Siddha Medical College, attached to 
Arignar Anna Government Hospital for Indian Medicine, Arumbakkam, Chennai – 
106. 
 
All necessary investigations were carried out to all patients and trial medicine 
was given. The results of before and after treatment of all the patients were analysed 
and discussed below. 
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AGE DISTRIBUTION: 
          Out of 40 cases 13 patients (32.5%) were between 21-25 years, 10 patients 
(25%) were between 15-20 years and 26-30 years, 5 patients (12.5%) were between 
31-35 years, 2 patients (5%) were between 36-40 years. 
 
DISRIBUTION OF KAALAM: 
   Among 40 patients, 38 patients (95%) were reported in vatha kaalam, 2 
patients (5%) were reported in pitha kaalam, and none of the patients were reported 
in kabha kaalam. 
   
              Majority of the patients were reported in their vatha kaalam (95%). 
 
            Soothaga vaayu which is resulting from the deranged vatha kutram has high 
incidence in vatha kaalam. 
 
OCCUPATION: 
         From selected 40 cases, 18 patients (45%) were student, 12 patients (30%) were 
working women, 10 patients (25%) were housewife. 
 
SOCIO ECONOMIC STATUS: 
           Regarding Socio Economic Status 17 patients (42.5%) were from middle 
income, 14 patients (35%) were from high income, 9 patients (22.5%) were from low 
income. 
 
FOOD HABITS: 
  Out of 40 cases, most of the cases 32 (80%) were taken mixed diet, and 8 
cases (20%) had vegetarian diet only. 
 
MARITAL STATUS: 
 Regarding marital status 21 patients (52.5%) were unmarried and 19 patients 
(47.5%) were married. 
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PARUVAKAALAM: 
 According to Paruvakaalam highest incidence of  22 cases (55%)  were noted 
in Pinpani kaalam and 18 cases (45%) were noted in Munpani kaalam. 
 
DISTRIBUTION OF THINAI: 
 According to the study, all 40 cases (100%) were from Neithal thinai. Neithal 
nilam was more prone to vatha disease. 
 
DISTRIBUTION OF VATHAM: 
 In all the 40 patients (100%) Abanan was affected resulting in irregular 
menstruation, constipation in some patients and inability to conceive 
        
     In 27 patients (67.5%) Vyanan was affected causing tiredness, low back pain 
and lower abdominal pain. 
 
 Devadhathan was affected in 15 patients (37.5%) having disturbed sleep and 
psychological stress. 
 
 In 10 patients (25%) Samanan was affected resulting in loss of appetite. 
 
DISTRIBUTION OF PITHAM: 
 Sathagapitham was affected in all cases producing irregular or absence of 
menstruation and inability to conceive. 
 
 In 13 patients (32.5%) Prasagam was affected causing hyper pigmentation of 
skin. 
 
 Analagam was affected in 10 patients (25%) causing loss of appetite. 
 
 Ranjagam was affected in 10 patients (25%) causing anaemia. 
 
DISTRIBUTION OF KABHAM: 
 Santhigam was affected in 15 patients (37.5%) causing low back pain. 
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 In 10 patients (25%) Kilethagam was affected causing loss of appetite. 
 
DISTRIBUTION OF UDAL THATHUKKAL; 
 Suronitham was affected in all 40 patients (100%) resulting in irregular 
menstruation, lack of ovulation and inability to conceive. 
 
 Saaram was also affected in all 40 patients (100%) resulting in tiredness and 
loss of appetite. 
 
 Enbu was affected in 15 patients (37.5%) resulting in low back pain. 
 
 Senneer was affected in 10 patients (25%) resulting in pallor of skin, eye and 
reduced haemoglobin. 
 
ENVAGAI THERVUGAL: 
 Naa was affected in 10 patients (25%) due to anaemic conditions (pale 
colour). 
 
 Niram was affected in 13 patients (32.5%) due to anaemia and 
hyperpigmentation in the neck and axillary region (Acanthosis Nigricans). 
 
           Vizhi was affected in 10 patients (25%) due to anaemic conditions (pale). 
 
 Malam was affected in 16 patients (40%) due to constipation. 
 
 Naadi was affected in all 40 patients (100%). 
 
Naadi: 
     Out of 40 patients, 27 patients (67.5%) had Vatha Pitham, 12 patients (30%)   
had Pitha Vatham, 1 patient (2.5%) had Kabha Pitham. 
 
NEIKURI: 
 Out of 40 patients 28 patients (70%) had Vatha Neer, 10 patients (25%) had 
Pitha Neer, 2 patients (5%) had Kabha Neer. 
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CLINICAL PROGNOSIS: 
 The clinical signs and symptoms were improved after treatment, showing only 
10 cases (25%) had Irregular menstruation, 2 cases (5%) had Oligomenorrhoea, 2 
cases (5%) had Dysmenorrhoea, 2 cases (5%) had Infertlity, 4 cases (10%) had 
Hirsutism, 8 cases (20%) had Acanthosis Nigricans. 
 
INVESTIGATIONS: 
 Investigations like TC, DC, ESR, Hb, Serum cholesterol and Blood sugar were 
examined and urine analysis for albumin, sugar and deposits were also examined. 
 
SPECIAL INVESTIGATION: 
 USG- abdomen and pelvis is advised for all the patients to confirm the 
diagnosis. USG pelvis was taken for all cases before treatment. They had bilateral 
polycystic ovaries. 
  
 Follicular study is advised for all patients.  
   
 After confirming the diagnosis, the patients were given the trial medicine and 
instructed to follow the diet and other restrictions based on Siddha system. 
 
BIOSTATISTICAL STUDY: 
            Since the p value is *p<0.005;**p<0.001 significant in all clinical 
manifestations. So there is significant reducing of clinical manifestations among the 
patients for the treatment of it is concluded that the treatment was effective and 
significant. 
 
RESULTS AFTER TREATMENT: 
 Clinical symptoms before and after treatment were noted to obtain prognosis 
of each clinical symptoms,   
 After treatment 75% of patients were relived from irregular menstruation, 60% 
of patients were relieved from oligomenorrhoea, 45% of patients were relieved from 
dysmenorrhoea, 5% of patients were relived from hirsutism, 5% of patients were 
relieved from A.nigricans.  
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          This dessertation study aims to make regulate the menstrual cycle and has to 
induce dominant follicle. 
OVERALL RESULT: 
 Out of 40 cases 27 (67.5%) had good result, 8 cases (20%) had moderate result 
and 5 cases (12.5%) had poor result.  
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                                                       SUMMARY 
 The clinical study on Soothaga vaayu was carried out in Post graduate 
department of Pothu Maruthuvam, Government Siddha Medical College, Arignar 
Anna Hospital, Chennai – 106 during the period of 2015-2018. 
   A total of 40 patients were treated in the Outpatient department. The clinical 
and pathological assessment was carried out on the basis of Siddha and Modern 
aspects. 
  All the patients were treated with Kalingathi Ennai  with warm water 15ml 
once a day, before food for 5 days, 3 consecutive menstrual cycles. 
 Most of the patients were in the age group between 21-25 years (32.5%). 
 
 Majority of the patients were reported in their vatha kaalam. 
 
 42.5% of the cases were in the Middle income group. 
 
 80% of the patients were Non-vegetarian. 
 
 Most of the patients were affected in Pinpani kaalam (55%). 
 
 Most of the patients were from Neithal thinai (100%). 
 
 In vatham, Abanan (100%), Vyanan (67.5%), Devadhathan (37.5%), 
Samanan (25%) were affected. 
 
 In Pitham, Sathagam (100%), Prasagam (32.5%), Analagam (25%), Ranjagam 
(25%) were affected. 
 
 In Kabham, Santhigam (37.5%), Kilethagam (25%) were affected. 
 
 In Ezhu udal kattugal, Saaram (100%), Senneer (25%), Enbu (37.5%), 
Suronitham (100%) were affected. 
                                                                                                                 SUMMARY 
 
 Page 112 
 
 
 In Envagai thervugal, Naa (25%), Niram (32.5%), Vizhi (25%), Malam 
(40%), Naadi (100%) were affected. 
 
 Regarding Naadi, Vatha pitha naadi (67.5%) was the most common naadi 
observed. 
 
 The toxicity study reveal that the trial medicine possesses no toxicity in 
animals. So it proved the safety of the trial medicine. 
 
 The pharmacological study of the medicine shows that the medicine possesses 
ovulation inducing activity. 
 
 Bio-statistical analysis of the clinical trial reveals significant p value < 0.005 
and < 0.001and concluded that the treatment is effective and significant. 
 
 The clinical trial shows that there is significant result in regulation of 
menstruation. 
 Out of 40 cases 27 (67.5%) had good result, 8 cases (20%) had moderate 
result and 5 cases (12.5%) had poor result.  
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                                            CONCLUSION 
 
 SOOTHAGA VAAYU occurs due to derangement of vatham and pitham 
which affects menstruation. 
 The trail medicine regularizes the menstrual cycle and induces ovulation. Thus 
it is beneficial in treating irregular menstruation and helps to regulate ovum 
maturation. 
 The KALINGATHI ENNAI reveals no toxicity in the preclinical studies and 
hence proved to be safe for human administration. 
 From the preclinical pharmacological study it is evident that, KALINGATHI 
ENNAI has significant ovulation inducing activity.  
 No adverse effect was reported during the course of the treatment. 
 From the clinical trial it is evident that the trial medicine regulates 
menstruation and induces dominant follicle. 
 Hence I conclude that the Siddha trial medicine KALINGATHI ENNAI will 
be a better medicine that can be used in the treatment of SOOTHAGA 
VAAYU. 
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ACUTE ORAL TOXICITY STUDY OF KALINGATHI ENNAI 
(OECD GUIDELINE – 423) 
 
Introduction: 
 The acute toxic class method is a stepwise procedure with the use of 3 animals 
of a single sex per step. 
 Depending on the mortality and/or the moribund status of the animals, on 
average 2-4 steps may be necessary to allow judgment on the acute toxicity of 
the test substance.  
 This procedure is reproducible, uses very few animals and is able to rank 
substances in a similar manner to the other acute toxicity testing methods.  
 The acute toxic class method is based on biometric evaluations with fixed 
doses, adequately separated to enable a substance to be ranked for 
classification purposes and hazard assessment.  
 In principle, the method is not intended to allow the calculation of a precise 
LD50, but does allow for the determination of defined exposure ranges where 
lethality is expected since death of a proportion of the animals is still the major 
endpoint of this test.  
 The method allows for the determination of an LD50 value only when at least 
two doses result in mortality higher than 0% and lower than 100%.  
 The use of a selection of pre-defined doses, regardless of test substance, with 
classification explicitly tied to number of animals observed in different states 
improves the opportunity for laboratory to laboratory reporting consistency 
and repeatability.  
 
Principle of the Test:  
It is the principle of the test that based on a stepwise procedure with the use of 
a minimum number of animals per step, sufficient information is obtained on the 
acute toxicity of the test substance to enable its classification. The substance is 
administered orally to a group of experimental animals at one of the defined doses. 
The substance is tested using a stepwise procedure, each step using three animals of a 
single sex. Absence or presence of compound-related mortality of the animals dosed 
at one step will determine the next step, i.e. 
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− no further testing is needed 
− dosing of three additional animals, with the same dose  
− dosing of three additional animals at the next higher or the next lower dose 
level. The method will enable a judgment with respect to classifying the test substance 
to one of a series of toxicity classes. 
 
Methodology: 
Selection of Animal Species  
 The preferred rodent species is the Wister albino rat, although other rodent 
species may be used. Healthy young adult animals are commonly used laboratory 
strains should be employed. Females should be nulliparous and non-pregnant. Each 
animal, at the commencement of its dosing, should be between 6 to 8 weeks old and 
the weight (150-200gm) should fall in an interval within±20 % of the mean weight of 
any previously dosed animals. 
  
Housing and Feeding Conditions 
 The temperature in the experimental animal room should be 22ºC + 3ºC.  
Although the relative humidity should be at least 30% and preferably not exceed 70% 
other than during room cleaning the aim should be 50-60%. Lighting should be 
artificial, the sequence being 12 hours light, 12 hours dark. For feeding, conventional 
laboratory diets may be used with an unlimited supply of drinking water. Animals 
may be group-caged by dose, but the number of animals per cage must not interfere 
with clear observations of each animal. 
 
Preparation of animals: 
The animals are randomly selected, marked to permit individual identification, 
and kept in their cages for at least 7 days prior to dosing to allow for acclimatization 
to the laboratory conditions 
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Test Animals and Test Conditions:  
 Sexually mature Female Wistar albino rats (150-200gm) were obtained from 
TANUVAS, Madhavaram, and Chennai. All the animals were kept under standard 
environmental condition (22±3 ° C).  The animals had free access to water and 
standard pellet diet (Saimeera foods, Bangalore). 
 
Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, 
and kept in their cages for at least 7 days prior to dosing to allow for acclimatization 
to the laboratory conditions 
Preparation for Acute Toxicity Studies 
Rats were deprived of food overnight (but not water 16-18 h) prior to 
administration of the, KALINGATHI ENNAI 
The principles of laboratory animal care were followed and the Institutional 
Animal Ethical Committee approved the use of the animals and the study design 
IAEC No: XLVIII/02/CLBMCP/2017 
 
Test Substance  : KALINGATHI ENNAI 
Animal Source  : Kings institute, Chennai.   
Animals   : Wister Albino Rats (Female-3+3) 
Age    : >6 weeks 
Body Weight on Day 0 :150-180 gm. 
Acclimatization  : Seven days prior to dosing. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number and individual  
                    marking by using Picric acid. 
Numberofanimals  : 3 Female/group,  
Routeofadministration :   Oral  
 
Diet : Pelletfeed supplied by Saimeera foods          
PvtLtd,Bangalore 
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Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages  
       provided with bedding of husk. 
Housing temperature : between 22ºC +3ºC.  
Relative humidity  : between 30% and 70%, 
Air changes    : 10 to 15 per hour and  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 14 Days 
 
Administration of Doses:  
 KALINGATHI ENNAI was administered to the groups of wistar albino rats in 
a single oral dose by gavage using a feeding needle. The control group received an 
equal volume of the vehicle. Animals were fasted 12 hours prior to dosing. Following 
the period of fasting, the animals were weighed and then the test substance was 
administered. Three Female animals are used for each group. The dose level of 20, 
100 and 200 mg/kg body weight was administered stepwise. After the substance has 
been administered, food was withheld for a further 3-4 hours. The principle of 
laboratory animal care was followed. Observations were made and recorded 
systematically and continuously as per the guideline after substance administration. 
The visual observations included skin changes, mobility, aggressively, sensitivity to 
sound and pain, as well as respiratory movements. Finally, the number of survivors 
was noted after 24 hrs and these animals were then monitored for a further 14 days 
and observations made daily. The toxicological effect was assessed on the basis of 
mortality. 
 
Observations:  
Animals are observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the 
first 4 hours, and daily thereafter, for a total of 14 days, except where they need to be 
removed from the study and humanely killed for animal welfare reasons or are found 
dead. It should be determined by the toxic reactions, time of onset and length of 
recovery period, and may thus be extended when considered necessary. The times at 
which signs of toxicity appear and disappear are important, especially if there is a 
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tendency for toxic signs to be delayed. All observations are systematically recorded 
with individual records being maintained for each animal. 
 
Observations include changes in skin and fur, eyes and mucous membranes, 
and also respiratory, circulatory, autonomic and central nervous systems, and 
somatomotor activity and behavior pattern. Attention was directed to observations of 
tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma. The principles 
and criteria summarized in the Humane Endpoints Guidance Document taken into 
consideration. Animals found in a moribund condition and animals showing severe 
pain or enduring signs of severe distress was humanly killed. When animals are killed 
for human reasons or found dead, the time of death was recorded. 
 
             Acute oral toxicity study of KALINGATHI ENNAI 
Table 1: Dose finding experiment and its behavioral Signs of acute oral Toxicity 
 
Observation done: 
SL 
Group 
CONTROL 
Observation SL 
Group 
TEST GROUP 
Observation 
1 Body weight Normal 1 Body weight 
 
Normally increased 
2 Assessments of posture Normal 2 
Assessments of 
posture 
Normal 
3 
Signs of Convulsion 
Limb paralysis 
Normal 3 
Signs of 
Convulsion 
Limb paralysis 
Absence of sign (-) 
4 Body tone Normal 4 Body tone Normal 
5 Lacrimation Normal 5 Lacrimation Absence 
6 Salivation Normal 6 Salivation Absence 
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7 Change in skin color 
No significant 
color change 
7 
Change in skin 
color 
No significant color 
change 
8 Piloerection Normal 8 Piloerection Normal 
9 Defecation 
Normal 
 
9 Defecation 
Normal 
 
10 Sensitivity response Normal 10 
Sensitivity 
response 
Normal 
11 Locomotion Normal 11 Locomotion Normal 
12 Muscle gripness Normal 12 
Muscle 
gripness 
Normal 
13 Rearing Mild 13 Rearing Mild 
14 Urination Normal 14 Urination Normal 
 
Behaviour: 
 The animals will be observed closely for behaviour in the first four hours 
which  includes abnormal gait, aggressiveness, exophthalmos, ptosis, akinesia, 
catalepsy, convolusion, excitation, head twitches, lacrimation, loss of corneal reflex, 
loss of traction, piloerection  reactivity of touch, salivation, scratching, sedation, 
chewing,  head movements, sniffing, straub, tremor and writhes, diarrhea, leathery, 
sleep and coma. 
 
Body Weight:  
Individual weight of animals was determined before the test substance was 
administered and weights will be recorded at day 1, 7, and 14 of the study. Weight 
changes were calculated and recorded. At the end of the test, surviving animals were 
weighed and humanly killed. 
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Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the treated dose 
groups.  
 
Mortality: 
Animals were observed for mortality throughout the entire period. 
 
Results: 
 All data were summarized in tabular form, (Table-1-4) showing for each test 
group the number of animals used, the number of animals displaying signs of toxicity, 
the number of animals found dead during the test, description of toxic symptoms, 
weight changes, food and water intake. 
 
No of animals in each group:3 
Table 2 (Observational study Results) 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. Control + - - + - + - - - - - - - - - - - - - - 
2. 
 
2000 
mg/kg 
 
+ - - + - + - - - - - - - - - - - - - - 
 
1..Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch 
Response 7. Decreased Motor Activity 8.Tremors 9.Convulsions 10. Muscle Spasm 
11. Catatonia 12. Muscle relaxant 13. Hypnosis 14.Analgesia 15.Lacrimation 
16.Exophthalmos 17.Diarrhea 18. Writhing  
19. Respiration 20. Mortality. 
 
(+  Present, -  Absent) 
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Table 3( Body weight Observation) 
 
Table 4 (Water intake (ml/day) of Wistar albino rats group exposed to 
(KALINGATHI ENNAI): 
 
N.S- Not Significant,**(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
 
Table 5: Food intake (gm/day) of Wistar albino rats group exposed to 
KALINGATHI ENNAI 
DOSE 
 
DAYS 
1 7 14 
CONTROL 32.56±2.16 32.92±3.26 30.92±3.26 
2000 mg/kg 34.12±8.64 34.31±1.22 35.22±2.24 
P value (p)* NS NS NS 
 
 
 
 
 
 
 
DOSE 
 
DAYS 
1 7 14 
CONTROL 176.21± 3.22 177.2± 4.27 179.2 ± 4.82 
2000 mg/kg 172.5± 3.18 174.2± 3.26 175.4 ± 3.27 
P value (p)* NS NS NS 
DOSE 
 
DAYS 
1 6 14 
CONTROL 38.7 ± 2.74 32.9± 4.33 33.4± 4.13 
2000 mg/kg 32.4±1.34 33.5±1.11 35. 9± 4.19 
P value (p)* NS NS NS 
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REPEATED DOSE 28-DAY ORAL TOXICITY STUDY OF KALINGATHI 
ENNAI 
Test Substance  : KALINGATHI ENNAI 
Animal Source  : Kings institute, Chennai.   
Animals   : Wister Albino Rats (Male -24, and Female-24) 
Age    : >6 weeks 
Body Weight    : 160-180 gm. 
Acclimatization  : Seven days prior to dose. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number   and    individual  
   marking by using    Picric acid 
Diet    : Pellet feed supplied by Saimeera foods Pvt Ltd,       
              Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages  
      provided with bedding of husk. 
Housing temperature : between 22ºC +3ºC.  
Relative humidity  : between 30% and 70%, 
Air changes    : 10 to 15 per hour  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 28 Days. 
 
Table 5  
 
 
 
 
 
Groups No of Rats 
Group I  Vehicle control (Normal Saline ) 12(6male,6 female) 
Group II KALINGATHI ENNAI20 mg/kg 12 (6male,6 female) 
Group III KALINGATHI ENNAI100 mg/kg 12 (6male,6female) 
Group IV KALINGATHI ENNAI200 mg/kg 12(6male,6female) 
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Methodology 
Randomization, Numbering and Grouping of Animals: 
48 Wistar Albino Rats (24M + 24F) were selected and divided into 4 groups. 
Each group consist of 12 animals (Male -6, and Female-6). First group treated as a 
control and other three group were treated with test drug (low, mid, high) for 28 days. 
Animals were allowed acclimatization period of 7 days to laboratory conditions prior 
to the initiation of treatment. Each animal was marked with picric acid. The females 
were nulliparous and non-pregnant. 
 
Justification for Dose Selection: 
         As per OECD guideline three dose levels were selected for the study. They are 
low dose (20 mg/kg), mid dose dose (100 mg/kg), high dose (200 mg/kg). X is 
calculated by multiplying the  dose  (2000mg/kg) i.eX low dose is 20 mg/kg/animal, 
5X mid dose is 100 mg/kg, 10X high dose is 200 mg/kg. 
 
Preparation and Administration of Dose: 
 KALINGATHI ENNAI was administered to animals at the dose levels of 20, 
100 and 200 mg/kg. The test substance suspensions were freshly prepared every two 
days once for 28 days. The control animals were administered vehicle only. The drug 
was administered orally by using oral gavage once daily for 28 consecutive days. 
 
Observations: 
Experimental animals were kept under observation throughout the course of 
study for the following: 
 
Body Weight: 
 Weight of each rat was recorded on day 0, at weekly intervals throughout the 
course of study. 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the 
treated dose groups.  
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Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity 
and duration of these symptoms, if any, were recorded. 
 
Mortality: 
All animals were observed twice daily for mortality during entire course of  
study. 
 
Necropsy: 
All the animals were sacrificed by excessive anesthesia on day 29. Necropsy 
of all animals was carried out. 
 
Laboratory Investigations: 
Following laboratory investigations were carried out on day 29 in animals 
fasted over-night. Blood samples were collected from orbital sinus using sodium 
heparin (200IU/ml) for Bio chemistry and potassium EDTA (1.5 mg/ml) for 
Hematology as anticoagulant. Blood samples were centrifuged at 3000 r.p.m. for 10 
minutes. 
 
Haematological Investigations: 
Haematological parameters were determined using Haematology analyzer.  
 
Biochemical Investigations:  
Biochemical parameters were determined using auto-analyzer. 
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Histopathology:  
Control and highest dose group animals will be initially subjected to 
histopathological investigations. If any abnormality found in the highest dose group 
than the low, then the mid dose group will also be examined. Organs will be collected 
from all animals and preserved in 10% buffered neutral formalin for 24 h and washed 
in running water for 24 h.  The organ sliced 5 or 6µm sections and were dehydrated in 
an auto technicon and then cleared in benzene to remove absolute alcohol. Embedding 
was done by passing the cleared samples through three cups containing molten 
paraffin at 50°C and then in a cubical block of paraffin made by the “L” moulds. It 
was followed by microtome and the slides were stained with Haematoxylin-eosin red. 
 
Statistical analysis:  
Findings such as body weight changes, water and food 
consumption,hematology and blood chemistry were subjected to One-way ANOVA 
followed by dunnet t test using a computer software programme – Graph pad  version 
5.0 .All data were summarized in tabular form, (Table-6 to 12) 
 
RESULTS 
Repeated Dose 28- day oral toxic study of KALINGATHI ENNAI 
Table 6: Body weight of wistar albino rats group exposed to KALINGATHI 
ENNAI 
 
NS- Not Significant, **(p > 0.01),*(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
DOSE 
 
DAYS 
1 7 14 21 28 
CONTROL 165.6±  2.76 166.4 ± 3.42 167.7 ± 3.26 169.2 ± 3.73 170.7 ± 1.31 
LOW DOSE 162.2 ± 4.12 162.7 ± 2.64 
163.9± 1.\ 
1 
164.9 ± 1.66 164.42± 2.76 
MID DOSE 167.6± 1.24 167.9 ± 4.74 169.4 ± 8.92 169.1 ± 6.36 170.7 ± 9.12 
HIGH DOSE 174.4± 3.74 174.6 ± 6.32 175.6 ± 2.86 176.1± 8.82 175.32 ± 2.42 
P value (p)* NS NS NS NS NS 
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Table 7: Water intake (ml/day) of Wistar albino rats group exposed to KALINGATHI 
ENNAI 
DOSE 
 
DAYS 
1 6 14 21 28 
CONTROL 31.5 ± 8.95 32.0 ±6.23 28.5±6.23 29.12±8.19 31.5±3.96 
LOW DOSE 29.5±3.31 29.9±6.62 31.7±4.02 32.2±4.29 34.9±3.13 
MID DOSE 30.7±3.93 30.3±3.11 30.1±2.83 31.4±2.11 31.4±1.14 
HIGHDOSE 31.1±1.12 31.2±2.43 32.7±2.53 33.2±1.89 34.4±2.45 
P value (p)* NS NS NS NS NS 
 
N.S- Not Significant, **(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
 
Table 8: Food intake (gm/day) of Wistar albino rats group exposed to 
KALINGATHI ENNAI 
DOSE 
 
DAYS 
1 7 14 21 28 
CONTROL 37.12 ±5.37 38.5±3.22 39.5±3.37 38.5±3.37 37.12±3.12 
LOW DOSE 33.7±2.12 35.3±1.42 35.9±1.68 36.4±2.62 35.9±8.42 
MID DOSE 34.2±3.64 35.9±3.64 36.2±6.15 37.4±2.18 35.2±2.64 
HIGH DOSE 35.2±2.14 35.2±2.18 36.6±2.14 37.2±4.28 37.2±2.18 
P value (p)* NS NS NS NS NS 
 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test 
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Table 9: Haematological parameters of Wistar albino rats group exposed to 
KALINGATHI ENNAI 
Category Control Low dose Mid dose High dose 
P value 
(p)* 
Haemoglobin(g/dl) 13.8±1.88 12.98±1.28 13.01±1.26 14.18±3.96 N.S 
Total WBC (×10
3
l) 11.91±2.59 12.25±3.53 12.18±3.61 12.96±3.47 N.S 
Neutrophils(%) 31.60±1.06 34.23±2.54 34.91±1.36 33.40±2.80 N.S 
lymphocyte (%) 68.32±2.48 70.22±3.42 71.48±2.66 71.20±3.96 N.S 
Monocyte (%) 0.80±0.17 0.81±0.12 0.84±0.11 0.95±0.16 N.S 
Eosinohil(%) 0.62±0.09 0.19±0.12 0.78±0.06 0.42±0.04 N.S 
Platelets 
cells10
3
/µl 
683.17±8.76 698.71±8.16 705.18±4.0 712.16±4.64 N.S 
Total RBC 10
6
/µl 7.96±0.12 6.82±1.87 6.92±0.59 6.18±0.72 N.S 
PCV% 36.75±0.6 36.35±1.53 38.2±1.18 36.82±2.14 N.S 
MCHC g/dL 32.6±2.23 34.19±1.19 35.18±1.92 34.13±1.94 N.S 
MCV fL(µm
3
) 48.15±3.64 48.20±1.24 49.28±1.24 49.99±1.84 N.S 
 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
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Table 10: Biochemical Parameters of Wistar albino rats group exposed to 
KALINGATHI ENNAI 
BIOCHEMICAL 
PARAMETERS 
CONTROL 
LOW 
DOSE 
MID DOSE 
HIGH 
DOSE 
P 
Value 
(p)* 
GLUCOSE (R) (mg/dl) 76.45±13.4 76.16±8.54 79.64±9.20 77.42±11.6 N.S 
T.CHOLOSTEROL(mg/dl) 115.26±1.83 112.45±1.13 112.42±1.98 115.22±1.83 N.S 
TRIGLY(mg/dl) 46.35±1.48 45.32±1.48 45.58±1.26 46.66±1.45 N.S 
LDL 72.81±2.13 70.14±2.34 71.8±2.94 72.64±6.12 NS 
VLDL 15.2±2.44 14.42±4.63 14.44±6.64 14.94±5.14 NS 
HDL 26.66±6.88 27.96±2.34 27.88±5. 66 29.78±6.22 NS 
Ratio1(T.CHO/HDL) 
4.42±2.44 4.36±1.44 4.84±2.44 4.86±1.92 NS 
Ratio 2(LDL/HDL) 
2.83±4.22 3.02±1.52 2.96±4.80 2.86±3.82 NS 
Albumin(g/dL) 3.63±0.17 3.13±1.12 3.10±1.92 2.94±3.86 NS 
  
NS- Not Significant,**(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
 
Table 11: Renal function test of ofWistar albino rats group exposed to 
KALINGATHI ENNAI 
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
UREA (mg/dl) 12.31±0.99 12.91±1.86 13.16±1.98 13.18±3.92 N.S 
CREATININE(mg/dl) 0.22±0.08 0.16±1.16 0.12±0.14 0.18±1.22 N.S 
BUN(mg/dL) 14.02±0.10 14.80±1.20 14.66±0.44 15.10±2.32 NS 
URIC ACID(mg/dl) 5.12±0.35 5.25±1.43 5.02±1.35 5.18±1.08 NS 
 
 NS- Not Significant, **(p > 0.01), * (p >0.05) , n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test 
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Table 12: Liver Function Test of ofWistar albino rats group exposed to 
KALINGATHI ENNAI 
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
T BILIRUBIN(mg/dl). 0.48±0.07 0.43±1.26 0.64±1.28 0.68±1.25 N.S 
SGOT/AST(U/L) 79.95±1.39 77.15±1.31 78.71±1.83 80.35±3.03 N.S 
SGPT/ALT(U/L) 31.23±1.28 31.81±3.52 30.14±3.18 31.9±1.88 N.S 
ALP(U/L) 143.25±8.70 141.9±8.17 142.16±4.10 144.33±4.25 NS 
T.PROTEIN(g/dL) 5.32±0.38 5.28±0.34 5.21±1.33 5.13±1.06 N.S 
 
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
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HISTO PATHOLOGY 
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      TEST GROUP (HIGH DOSE) 
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    PHARMACOLOGICAL ACTIVITY 
OVULATION INDUCING ACTIVITY OF KALINGATHI ENNAI  
 
ANIMAL PROCUREMENT AND MAINTENANCE: 
  Female Wistar albino rats weighing about 150-200g were purchased from 
Kings Institute of Preventive medicine animal house, Chennai, India. Animal ethical 
guidelines of CPCSEA, Ministry of Animal Husbandry and Welfare, Govt. of India 
were strictly followed for the care and maintenance of procured animals. The animals 
were fed on standard rodent pellet and RO Water was provided ad libitum. The 
animals were kept for overnight fasting before experimentation. 
 
Method   
Before starting drug treatment, the reproductive cycles of the rats were 
synchronized by the following method. 100μg estradiol dissolved in 2 ml olive oil 
was injected subcutaneously. All rats after a 24 hr period, received intramuscular 
injections of 50 μg progesterone dissolved in olive oil. After few hours, vaginal 
smears were obtained by vaginal lavage to monitor ovulation and oestrous cycle. 
Vaginal smears were prepared by washing vaginal opening with 0.9% w/v of sodium 
chloride with a glass dropper and placed in a clean glass slide and viewed under light 
microscope at 40X magnification. Examination of vaginal smears showed that all the 
animals were in the oestrous stage. 
 
 All the animals were weighed daily after drug administration for 10 days. The 
suitable sensitive rats were divided into four groups of six each as follows  
Experimental design 
 Group I Normal Control animals 1ml/kg of CMC solution.  
 Group II rats were administered Kalingathi ennai100mg/kg for 10days,  
 Group III rats were administered Kalingathi ennai 200mg/kg for 10 days  
 Group IV received Clomiphene 10mg/kg and served as standard. All the drugs 
were given orally. 
After that 2ml of blood was collected by retro orbital puncture. Blood samples 
were centrifuged for 15 minutes at 4000 rpm and the separated serum samples were 
frozen at -20°C and kept for later estimation of LH, FSH and Estradiol by ELISA 
method.  
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4.4.2 Hormonal assay  
Biochemical assay  
The method employed was Microwell Enzyme Linked Immunosorbent Assay 
(ELISA) using analytical grade reagents.  
 
Estimation of serum luteinizing hormone (LH)  
The method employed was Microwell immunoassay (ELISA) using analytical 
grade reagents. 0.050ml of the serum was pipetted into the assigned wells. 0.001ml of 
LH-Enzyme reagent was added to all the wells. The microplate was swirled for 20-30 
seconds and covered, this mixture was allowed to incubate for 60 minutes at room 
temperature. After which, the contents were discarded by decantation. 350µl of wash 
buffer was added and decanted for 3 times. 100µl of working substrate solution was 
added to all the wells and was allowed to incubate for fifteen minutes. 50µl of stop 
solution was added to all the wells and gently mixed for 20 seconds. The optical 
density was read at 450nm in a microplate reader within 30mins. The mean 
absorbance values for each set of standards, controls, and test samples were calculated 
and a standard curve was constructed by plotting a mean absorbance obtained from 
each of the reference standard against its concentration from the standard curve. 
 
Estimation of serum follicle stimulating hormone (FSH)  
The method employed was Microwell immunoassay (ELISA) using analytical 
grade reagents. 0.050ml of the serum was pipetted into the assigned wells. 0.001ml of 
FSH-Enzyme reagent was added to all the wells. The microplate was swirled for 20-
30 seconds and covered, this mixture was allowed to incubate for 60 minutes at room 
temperature. After which, the contents were discarded by decantation. 350µl of wash 
buffer was added and decanted for 3 times. 100µl of working substrate solution was 
added to all the wells and was allowed to incubate for fifteen minutes. 50µl of stop 
solution was added to all the wells and gently mixed for 20 seconds. The optical 
density was read at 450nm in a microplate reader within 30mins.The mean 
absorbance values for each set of standards, controls, and test samples were calculated 
and a standard curve was constructed by plotting a mean absorbance obtained from 
each of the reference standard against its concentration from the standard curve  
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Determination of serum progesterone levels  
The method employed was Microwell immunoassay (ELISA) using analytical 
grade reagents. 0.025ml of the serum was pipetted into the assigned wells. 0.050ml of 
progesterone Enzyme reagent was added to all the wells. The microplate was swirled 
for 20 seconds to mix, 0.050ml progesterone biotin reagent was added to all the wells, 
the mixture was swirled for 20 seconds to mix and covered, this mixture was allowed 
to incubate for 60 minutes at room temperature. After which, the contents were 
discarded by decantation. 350µl of wash buffer was added and decanted for 3 times. 
100µl of working substrate solution was added to all the wells and was allowed to 
incubate for twenty minutes. 50µl of stop solution was added to all the wells and 
gently mixed for 20 seconds. The optical density was read at 450nm in a microplate 
reader within 30mins. The mean absorbance values for each set of standards, controls, 
and test samples were calculated and a standard curve was constructed by plotting a 
mean absorbance obtained from each of the reference standard against its 
concentration from the standard curve.  
 
Determination of serum Estradiol levels  
The method employed was Microwell immunoassay (ELISA) using analytical 
grade reagents. 0.025ml of the serum reference was pipetted into the assigned wells. 
0.050ml of Estradiol Biotin reagent was added to all the wells. The microplate was 
swirled for 20 seconds to mix, the mixture was incubated at room temperature for 
30mins,0.050ml Estradiol enzyme reagent was added to all the wells , the mixture was 
swirled for 20 seconds to mix and covered, this mixture was allowed to incubate for 
90 minutes at room temperature. After which, the contents were discarded by 
decantation. 350µl of wash buffer was added and decanted for 3 times. 100µl of 
working substrate solution was added to all the wells and was allowed to incubate for 
twenty minutes. 50µl of stop solution was added to all the wells and gently mixed for 
20 seconds. The optical density was read at 450nm in a microplate reader within 
30mins. The mean absorbance values for each set of standards, controls, and test 
samples were calculated and a standard curve was constructed by plotting a mean 
absorbance obtained from each of the reference standard against its concentration 
from the standard curve 
 
                                                                             PHARMACOLOGICAL ACTIVITY 
 
 Page 139 
 
Effect of Kalingathi ennai on Serum Concentration of reproductive hormones of 
female Wister albino rat  
S. 
No 
Group 
Treatment 
and dose 
LH 
(IU/ml) 
FSH  
(IU/ml) 
Estrodial 
(pg/ml) 
Progesterone 
(pg/ml) 
1. Normal 
2ml/kg 2% 
CMC 
0.280.12 0.330.24 54.103.5 9.031.65 
2. 
Low 
dose 
KGE 100 
mg /kg 
0.360.09 0.460.20 
38.32 
2.6 
6.61.14 
3. 
High 
dose 
KGE 200 
mg /kg 
0.430.14 
0.55 
0.16 
32.68 
2.1 
6.40.46 
4. Standard 
Clomiphene 
10mg/kg 
0.560.27 
0.63 
0.21 
27.17 
1.8 
5.90.86 
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ANNEXURE-II 
BIO-CHEMICAL ANALYSIS OF TRIAL MEDICINE 
 
S.No EXPERIMENT OBSERVATION INFERENCE 
I                                    TEST FOR ACID RADICALS 
1a Test for Sulphate 
2 ml of the above prepared 
extractis taken in a test tube. To 
this add2ml of 4% Ammonium 
oxalatesolution. 
Absence of 
White Precipitate 
Absent 
b 2ml of extract is added with 2mlof 
dilute hydrochloric acid untilthe 
effervescence ceases off. Then2ml 
barium chloride solution isadded. 
Absence of 
White Precipitate 
Absent 
2 Test for Chloride: 
2ml of extract is added with 
dilutenitric acid till the 
effervescenceceases. Then 2ml of 
silver nitratesolution is added. 
Absence of white 
precipitate 
 
Absent 
3 Test for Phosphate 
2ml of the extract is treated 
with 2 ml of Ammonium 
molybdate solution and 2ml of 
concentrated nitric acid. 
 
Absence of yellow 
precipitate 
 
Absent 
4 Test for Carbonate: 
2ml of the extract is treated 
with 2ml of magnesium 
sulphate solution. 
 
Absence of white 
precipitate 
Absent 
5 Test for Sulphide: 
1 gm of the substance is treated 
with 2ml of concentrated 
Hydrochloric acid 
 Absence of rotten 
egg smelling 
Absent 
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6 Test for Nitrate: 
1gm of the substance is heated 
with copper turnings and 
concentrated sulphuric acid 
and viewed the test tube 
vertically down. 
Absence of reddish 
brown gas. 
Absent 
 
7a Test for Fluoride and oxalate 
2ml of the extract is added with 
2ml of dilute acetic acid and 
2ml of calcium chloride 
solution and heated. 
 White precipitate 
absent 
Absent 
b 5 drops of clear solution is 
added with 2ml of dilute 
sulphuric acid and slightly 
warmed to this, 1 ml of dilute 
potassium permanganate 
solution is added. 
 
 Absence of KMNO4 
solution 
Discolourisation  
Absent 
8 Test for Nitrite 
3 drops of the extract is placed 
on a filter paper. On that, 2 
drops a Acetic Acid and 2 
drops of Benzidine solution is 
placed. 
 
Absence of 
yellowish red colour 
Absent 
9 Test for Borate 
2 pinches of the substance is 
made into paste by using 
Sulphuric acid and Alcohol 
(95%) and introduced into the 
blue flame. 
Absence of Green 
tinged flame 
Absent 
II                                     TEST FOR BASIC RADICALS 
10 Test for lead Absence of Yellow Absent 
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2 ml of the extract is added 
with 2 ml of Potassium iodide 
solution. 
precipitate 
11a Test for Copper 
One pinch of substance is 
made into paste with 
concentrated Hydrochloric acid 
in a watch glass and introduced 
into the non luminous part of 
the flame. 
Absence of Bluish 
green coloured 
flame. 
Absent 
b 2ml of the extract is added with 
excess of Ammonia solution 
Aresence of deep 
blue 
Absent 
12 Test for Aluminium 
To the 2 ml of extract. Sodium 
Hydroxide solution is added in 
drops to excess. 
 
Absence of White 
Precipitate. 
Absent 
13a Test for Iron 
To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate 
Solution is added. 
 Absence of Blood 
red colour            
Absent 
b To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate 
solution and 2 ml of 
concentrated HNO3 isadded. 
Absence of blood red 
colour. 
Absent 
14 Test for Zinc 
To the 2 ml of extract Sodium 
Hydroxide solution is added in 
drops to excess. 
Absence of White 
precipitate. 
Absent 
15 Test for Calcium 
2 ml of the extract is added 
with 2 ml of 4% Ammonium 
Oxalate solution. 
Absence of White 
precipitate. 
Absent 
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16 Test for Magnesium 
2ml of extract, Sodium 
Hydroxide solution is added in 
drops to excess. 
Absence of White 
precipitate. 
Absent 
17 Test for Ammonium 
2 ml of extract few ml of 
Nessler’s Reagent and excess 
of Sodium Hydroxide solution 
are added. 
Absence of 
Reddish brown 
precipitate 
Absent 
18 Test for Potassium 
A pinch of substance is treated 
with 2 ml of Sodium Nitrite 
solution and then treated with 2 
ml of Cobal Nitrate in 30% 
glacial Acetic acid. 
Absence of Yellow 
precipitate 
 
Absent 
19 Test for Sodium 
2 pinches of the substance is 
made into paste by using 
Hydrochloric acid and 
introduced into the blue flame 
 
Absence of Yellow 
colour flame 
Absent 
20 Test for Mercury 
2 ml of the extract is treated 
with 2 ml of Sodium 
Hydroxide solution. 
 
Absence of yellow 
precipitate 
Absent 
21 Test for Arsenic 
2 ml of extract is treated with 2 
ml of silver Nitrate solution 
Absence of 
Yellow precipitate 
Absent 
22 Test for Starch 
2ml of extract is treated with 
weak iodine solution 
Absence of 
Blue colour 
Absent 
23 Test of reducing Sugar 
5ml of Benedicts qualitative 
Presence of Green 
colour  
Present 
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solution is taken in a test tube 
and allowed to boil for 2 
minutes and added 10 drops of 
the extract and again boiled for 
2 minutes. The colour changes 
are noted. 
24 Test of the alkaliods 
2ml of the extract is treated 
with 2ml of potassium Iodide 
solution. 
Absence of 
Red colour 
Absent 
25 Test of the proteins 
2ml of the extract is treated 
with 2ml of 5% NaOH ,mix 
well and add 2 drops of copper 
sulphate solution. 
Absence of 
Violet colour 
Absent 
 
RESULTS: 
The given sample (Kalingathi ennai) contains  Reducing sugar. 
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                                    BIOSTATISTICAL ANALYSIS 
 
CLINICAL PROGNOSIS 
TREAMENT FOR SOOTHAGA VAAYU 
The most popular non parametric statistical tool, namely, McNemar Test analysis has 
been employed to analyses the effectiveness with the help of a hypothesis. 
S.No 
Signs and Symptoms 
Before Treatment After Treatment 
 n% n% 
1. Irregular menstruation 40(100) 10(25)** 
2. Oligomenorrhoea 26(65) 2(5)** 
3. Dysmennorrhoea 20(50) 2(5)** 
4. Infertility 4(10) 2(5)* 
5. Hirsutism 6(15) 4(10)* 
6. Acanthosis nigricans 10(25) 8(20)* 
 
McNemat test, C.I: 95%, *P<0.005; **P<0.001 
 
Software: spss 17 version 
 
Number of cases: 40 
Inference: 
       Since the p value is significant in all signs and symptoms. So there is significant 
reducing of signs and symptoms among the patients for the treatment of Soothaga 
vaayu. Hence it is concluded that the treatment was effective and significant.  
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   GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
     CHENNAI – 600 106 
 
CLINICAL STUDY ON “KALINGATHI ENNAI” IN THE TREATMENT OF 
       “SOOTHAGA VAAYU” (POLYCYSTIC OVARIAN SYNDROME) 
 
                       INFORMED CONSENT FORM 
 
“I have read the foregoing information. I have had the opportunity to ask 
questions about it and any questions I have asked have been answered to my 
satisfaction. 
 
              I   consent voluntarily to participate in this study and understand that I have 
the   right to withdraw from the study at any time without in any way it affecting my 
further medical care”. 
 
"I have received a copy of the information sheet/consent form". 
    
Date:  
   
Station:    
                                                                               
Signature of participant:  
 
Signature of the Guide:             Signature of theInvestigator:   
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       murpdh; rpj;j kUj;Jtf; fy;Yhh;p nrd;id 106 
         mwpQh; mz;zh kUj;Jtkid nrd;id 
  
    #jfthA Neha;f;fhd rpj;j kUe;jpd; (fypq;fhjp vz;nza;) 
ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;fhd jfty; gbtk;  
                   xg;Gjy; gbtk; 
   
Ma;thsuhy; rhd;wspf;fg;gl;lJ 
 
          ehd; ,e;j Ma;it Fwpj;j midj;J tpguq;fisAk; 
Nehahspf;F GhpAk; tifapy; vLj;Jiuj;Njd; vd cWjpaspf;fpNwd; 
  
Njjp :                               ifnahg;gk; : 
,lk; :                               ngah; : 
 
                  Nehahspapd; xg;Gjy; 
     vd;dplk; ,e;j kUj;Jt Ma;tpd; fhuzj;ijAk;, kUe;jpd; jd;ik 
kw;Wk; kUj;Jt topKiw gw;wpAk;, njhlh;e;J vdJ cly; ,af;fj;ij  
fz;fhzpf;fTk; ,mjid ghJfhf;fTk; gad;gLk; kUj;Jt Ma;Tf;$l 
ghpNrhjidfs; gw;wp jpUg;jp mspf;Fk; tifapy; Ma;T kUj;Jtuhy;    
tpsf;fpf; $wg;gl;lJ. 
ehd; kUj;Jt Ma;tpd; NghJ ,fhuzk; vJTk; $whky; ,vg;nghOJ 
Ntz;LkhdhYk; ,e;j Ma;tpypUe;J vd;id tpLtpj;J nfhs;Sk; 
chpikia njhpe;jpUf;fpd;Nwd.; ehd; vd;Dila Rje;jpukhf Njh;T 
nra;Ak; chpikiaf; nfhz;L  #jfthA Neha;f;fhd fypq;fhjp 
vz;nza; kUe;jpd; gufupg;Gj; jpwidf; fz;lwpak; kUj;Jt Ma;tpw;F 
vd;id cl;gLj;j xg;Gjy; mspf;fpNwd;.  
 
Njjp :                                    ifnahg;gk; : 
,lk; :                                       ngah; :  
 
CwTKiw:                        rhl;rpf;fhuh; ifnahg;gk;                                                                 
;                                            ngah; : 
Njjp : 
,lk; : 
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CASE SHEET PROFORMA 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
POST GRADUATE DEPARTMENT – MARUTHUVAM BRANCH 
CHENNAI – 600 106. 
 
CASE SHEET PROFORMA FOR SOOTHAGA VAAYU 
(POLYCYSTIC OVARIAN SYNDROME – PCOS) 
 
OP No / IP No  :    Nationality : Indian 
 
Ward No  :    Religion :  
 
Bed No  :    D.O.A  : 
 
Name  
(In Block Letters) :    D.O.D  : 
 
Age   :    No of Days 
       Treated  : 
Sex   : Male/ Female    
 
Occupation  :    Diagnosis : 
 
Income  :  /Month Result  : 
 
Permanent Address : 
 
 
 
 
Temporary Address : Govt. Siddha Medical College, 
  Chennai – 600 106. 
 
 
1. Complaint and duration  : 
 
 
 
2. History of present illness  : 
 
 
 
3. History of previous illness  : 
 
 
 
4. Personal history 
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 Marital History  : 
 Duration of married life : 
 Food               : 
 Abortion   : 
5. Menstrual history   : 
            Regularity of cycle                 : 
            Length of cycle (Days)           : 
            Duration of flow (Days)         : 
            Level of flow                          : 
            Abdominal pain                      : 
            LMP                                        : 
6. Occupational history                       : 
7. Personal habits                                : 
8. Family history                                 : 
 
GENERAL EXAMINATION: 
Body built 
Anaemia 
Jaundice 
Cyanosis 
Clubbing 
JVP 
Tracheal deviation 
Pedal oedema 
Lymph adenopathy 
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VITAL SIGNS 
  Temperature 
            Pulse 
     Respiratory rate 
       Blood Pressure 
            Weight 
            Height 
            Hirsutism 
            Acanthosis nigricans 
 
SIDDHA ASPECT 
 
1. NILAM: 5 
 Kurinji 
 Mullai 
 Marutham 
 Neithal 
 Paalai 
2. PARUVA KAALAM: 6 
 Kaar Kaalam   : (Aavani, Purattasi) 
 Koothir Kaalam : (Ayppasi, Karthigai) 
 Munpani Kaalam : (Maarkazhi, Thai) 
 Pinpani Kaalam : (Maasi, Panguni) 
 Elavenil Kaalam : (Chittirai, Vaikasi) 
 Mudhuvenil Kaalam : (Aani, Aadi)  
3. UDAL: 4 
  Vali Udal 
  Azhal Udal 
  Iya Udal 
  Kalappu Udal 
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4. KANMENTHIRIYANGAL: 5 
  Vaai 
  Kaal 
  Kai 
  Eruvai 
  Karuvai 
5. PORI / PULANGAL: 5 
 Mei - Ooru 
Vaai - Suvai 
Kann - Oli 
Mookku - Nattram 
Sevi - Osai 
6. GUNAM: 3 
 Sathuva Gunam 
 Rajo Gunam  
 Thamo Gunam 
7. UDAL KATTUGAL: 7 
 Saaram 
 Senneer 
 Oon 
 Kozhuppu 
 Enbu 
 Moolai 
 Sukkilam / Suronitham 
 
8. MALAM: 3 
  Malam 
 Moothiram 
 Viyarvai 
9. MUKKUTRANGAL 
 VALI 
   Piraanan 
   Abaanan 
   Uthaanan 
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   Viyaanan 
   Samaanan 
                         Nagan 
                         Koorman 
                         Kirukaran 
                         Devathathan 
                         Thananjeyan   
  AZHAL 
   Anala Pitham 
   Ranjaga Pitham 
   Aalosaga Pitham 
   Praasaga Pitham 
   Saathaga Pitham 
  IYAM 
   Avalambakam 
   Kilethagam 
   Pothagam 
   Tharpagam 
   Santhigam 
10. ENVAGAI THERVU 
  Naadi 
  Sparisam 
  Naa 
  Niram 
  Mozhi 
  Vizhi   
  Malam 
Niram 
   Irugal 
   Ilagal 
             Moothiram 
  Neerkuri: 
Niram 
Edai 
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Manam 
Nurai 
Enjal 
Neikuri: 
SIGNS AND SYMPTOMS 
 
1. Irregular menstruation 
2. Oligomenorrhoea 
3. Dysmenorrhoea 
4. Hirsutism 
5. Acanthosis nigricans 
 
INVESTIGATION 
A)BLOOD INVESTIGATIONS: 
  
 
BLOOD INVESTIGATIONS 
 
BEFORE 
TREATMENT 
 
AFTER 
TREATMENT 
Hb  (gms/dl)   
T.RBC (millions cells/cu.mm)   
 
ESR (mm) 
½ hr   
1 hr   
T.WBC (cells/cu.mm)   
Differential  
Count (%) 
Polymorphs   
Lymphocytes   
Monocytes   
Eosinophils   
Basophils   
Blood Sugar ( R ) mg/dl   
Serum Cholesterol (mg/dl)   
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B) URINE INVESTIGATIONS: 
 
 
URINE INVESTIGATIONS 
 
BEFORE 
TREATMENT 
 
AFTER 
TREATMENT 
Albumin   
Sugar   
Deposits   
 
C) SPECIFIC INVESTIGATIONS: 
USG- Whole Abdomen 
Follicular Study 
 
D)BODYMASS INDEX (BMI) 
 
 
SIGN AND SYMPTOMS: 
 
 
S.No 
 
CLINICAL 
FEATURES 
 
BEFORE 
TREATMENT 
 
AFTER TREATMENT 
1
st
 cycle 2
nd
 cycle 3
rd
 cycle 
1 Regularity of 
cycle 
    
2 Length of cycle     
3 Duration of flow     
4 Level of flow     
5 Abdominal pain     
6 Low back pain     
7 Hirsutism     
8 Acanthosis 
nigricans 
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DIAGNOSIS 
SOOTHAGA VAAYU  (POLYCYSTIC OVARIAN SYNDROME) 
TRIAL DRUG :  KALINGATHI ENNAI 
 DOSE : 15ml 
Anubanam: WARM WATER 
 Duration of Treatment : 3 consecutive menstrual cycles  
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